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Pregnancy Associated Breast Cancer: an Analysis of Fetal Treatment Risk
Melissa Barnett
Abstract
There are several viable treatment options for patients with PABC considered un-harmful
to fetal development. Trastusumab, or Herceptin, targets HER2 protein and successfully combats
aggressive breast cancer. In standard doses, it appears to be safe to the fetus even when
administered during the first trimester. A likely side effect of Herceptin is anhydramnios, which
can be monitored for throughout the stages of a pregnancy (Shrim et al. 2008). Anthracyclines,
commonly used in chemotherapy, appear to be non-toxic, and have been used to successfully
cure PABC patients in their second and third trimester. However, first trimester spontaneous
abortions are documented to increase dramatically in anthracycline receiving PABC patients
(Ring A. E. et al. 2005). Taxanes, such as paclitaxel, docetaxel, and vinorelbine, are microtubule
agents that are highly active against breast cancer. As cytotoxic drugs they can possibly disrupt
organogenesis and their administration should therefore be delayed until after the first trimester.
Taxanes as well as anthracycline treatments should also be halted three weeks prior to delivery to
prevent the occurrence of neutropenia, a decrease in white blood cells (neutrophil) that raises the
risk of infection, and allow for regeneration of platelet count in the bloodstream (Mir O. et al
2008). Breast surgery can be safely performed at any point of a pregnancy although it is
recommended to be postponed until after the first trimester. External beam radiation and
hormone therapy are both documented to have negative effects on a developing fetus and
therefore should not be considered as possible treatment options for PABC patients. In
diagnosing and assessing PABC, ionizing radiation should be replaced by chest x-rays
accompanied with proper shielding to protect the fetus. Sonograms appear to be more effective
in diagnosing breast cancer than mammograms, because of the changes in pregnancy related
breast density. Although PABC treatment is more complicated than standard breast cancer
treatment, treatment during pregnancy has been proven to be a feasible and recommended option
(Loibl S. et al. 2005).
Introduction
Pregnancy Associated Breast Cancer (PABC) presents a treatment plan quandary. The
diagnosis appears to present a conflict between the mother and fetus’ health. The challenge
facing the health care provider is how to balance the mother’s cancer care, with the fetus’ prenatal care. The aim of the physicians is to provide optimal treatment to the mother so as to
maximize her chances of survival whilst minimizing risk to the fetus. This will often require an
extensive healthcare group consisting of an OBGYN, a medical oncologist, radiation oncologist,
pediatricians, and sometimes a breast surgeon. This complex scenario arises in approximately
three percent of breast cancer cases. However, this statistic is likely to increase as women are
increasingly delaying pregnancy until a later age (Ring A. E. et al 2005). It is therefore crucial to
gain a clear understanding of this commonly misconceived situation.
It has generally been the public supposition that a woman with cancer who was found to
Melissa Barnett, BS ’09 graduated Touro with a degree in Biology. She is currently in a B.S.N program at Seton
Hall University.
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be pregnant would have to choose: her life or her baby’s. However, with the publication of many
more case studies it has become evident that, at least in regard to breast cancer, this is not the
case. It has been shown through controlled case studies that the prognosis for women who
undergo voluntary abortion is not more favorable than for those women who continue their
pregnancy (Gottlieb S. 1999). Analysis of the treatment options will support the recommended
course of treatment to the highest possible standard despite the difficulties in the diagnosis and
treatment of breast cancer.
The major difficulties in diagnosing breast cancer in a pregnant woman arise from the
physiological changes that occur in the breast, and from the inability to use certain staging
investigative procedures that are normally used in non-pregnant women. Mammograms have
been shown to be relatively ineffectual in pregnant women because they are too hard to interpret
due to the increased breast density in pre-menopausal and pregnant women. Therefore,
sonography is more often the method of choice to diagnose PABC. There are also many routine
staging investigations for breast cancer that use ionizing radiation, which should certainly not be
used on a pregnant woman within the first trimester. In addition, not enough proof is available to
support the safety of this technique for the fetus even during the later stages of pregnancy.
Instead, chest X-rays are considered relatively safe in pregnancy when proper shielding is used
(Ring A. E. et al 2005a).
Treatment for breast cancer is manifold. There are various options and each case must be
individually assessed to design a treatment plan that will work. The basic care recommendations
are breast surgery, radiation, systemic chemotherapy and other cytotoxic drugs, hormone
therapy, and supportive care. Breast surgery may be performed throughout pregnancy, however,
because there is a greater chance of spontaneous abortion within the first trimester. It is
recommended that surgery be postponed until the second or third trimesters and that fetal activity
be monitored throughout surgery. External beam radiation is contraindicated during pregnancy
because of the serious risks associated with fetal exposure, such as mental retardation and other
malformations. Hormone therapy should be postponed until after delivery, because defects have
been seen in mice studies; there have been reports of Goldenhar’s syndrome and of ambiguous
genitalia in children born to women exposed to hormone therapies. Supportive care for
anthracycline-based chemotherapy is safe after the first trimester (Loibl S. et al 2005). The use of
systemic chemotherapy is dependent on the drug type and the trimester in which it is used.
Research on cytotoxic drugs is ongoing and is mostly confined to case studies and individual
case reports. There are several specific drugs that deserve further analysis. They are:
Trastuzumab or Herceptin, anthracycline-based drugs such as the doxorubicin,
cyclophosphamide, and fluorouracil combination, and taxanes or anti microtubule agents such as,
docetaxel, paclitaxel, and vinorelbine.
Trastuzumab
Trastuzumab, generically also known as Herceptin, is an IgG1 monoclonal antibody that
is directed against the 2(HER2)protein. The HER2 protein is a member of the epidermal growth
factor receptor family. In recent years, researchers have found that in certain breast cancer cases
this protein can be over expressed. When this occurs it causes increased cell growth and
proliferation leading to a much more aggressive breast cancer. This type of cancer was
considered one of the more fatal breast cancers until the advent of drugs like trastuzumab that
target this protein. The drug has been shown to significantly improve outcomes in patients with
5

HER2-positive breast cancer (Shrim A. et al 2008). Because HER2 over-expression has been
found in up to 35% of breast cancer cases in young patients (<35 years), it is probable that it will
be concurrent with PABC. Therefore, trastuzumab may be necessary during pregnancy, and the
risk factors must be analyzed.
Epidermal growth factor receptors seem to be important in fetal development. HER2 is
expressed in embryofetal tissue. Therefore, it might be critical to fetal development. It has also
already been demonstrated that transplacental transfer of maternal monoclonal IgG1 antibodies is
possible. It is therefore reasonable to expect that trastuzumab might cross the placental barrier
(Witzel I. D. et al 2007). In this regard, however, animal research has not exhibited any fetal
harm. Reproduction studies were conducted in monkeys at 25 times the weekly human dose, and
no decrease in fertility or fetal harm were noted. This study indicates that more research is
required on the exact mechanism of action of the HER2 protein in fetal development (Shrim A et
al 2008).
There are several reports of case studies where trastuzumab was part of the treatment in a
pregnant breast cancer patient. With this particular drug, there does not seem to be increased
harm to the fetus if it is administered during the first trimester. This conclusion is drawn from the
case of a patient presenting with metastatic breast cancer who was treated with trastuzumab at
normally recommended doses throughout the first 24 weeks of her pregnancy. She underwent a
caesarean section at 37 weeks and was delivered of a healthy baby. However, in another case a
woman received 25 cycles of trastuzumab before becoming pregnant, then nine more cycles
during pregnancy, and in this case, the fetus was affected. Because the mother presented at 27
weeks pregnant with severe vaginal bleeding, the baby was delivered preterm at 28 weeks via
caesarean section. The baby suffered several disorders and died 21 weeks later due to multiple
organ failure. This second case does not specifically indicate that trastuzumab caused the
irregularities in the fetus because they could be related purely to prematurity. However, in this
case the drug dose to the mother was much higher, which could indicate that despite reassuring
findings in other research, higher doses of the drug could affect fetal development and result in
an impaired prognosis of the newborn.
Treatment after the first trimester does not appear to result in long term fetal harm. There
are two case studies of women with metastatic breast cancer who underwent trastuzumab
treatment during the second trimester and had no reports of any disorders. One woman was
treated until 24 weeks gestation, and the other started treatment at 27 weeks gestation and
delivered a healthy male at 34 weeks. The other case reports of women treated with the drug
during the second or third trimesters all document a condition called anhydramnios, a lack of
amniotic fluid. One patient was treated with trastuzumab until 23 weeks when anhydramnios was
diagnosed, and treatment was discontinued. The anhydramnios resolved itself after
discontinuation of the drug and a healthy baby was delivered at 37 weeks. Two other patients
underwent trastuzumab treatment in their second and third trimesters and suffered anhydramnios.
In one case the mother received treatment from her 26th week to her 32nd week when a caesarean
section was performed. The baby showed signs of several dysfunctions, however these were
probably related to its prematurity, and were resolved. The child’s further development was
normal. In the second case, a mother treated at weekly intervals until 35 weeks gestation when
labor was induced, showed persistent anhydramnios throughout treatment. However, she was
delivered of a healthy baby. It appears that trastuzumab treatment is possible during pregnancy
6

with close monitoring of the fetus, especially monitoring of fetal renal function and amniotic
fluid volume (Witzel I. D. 2007).
Anthracycline Based Chemotherapeutic Drugs
Anthracyclines are a drug species that damage DNA through different mechanisms. One
of these mechanisms is topoisomerase IIalpha poisoning. Since topoisomerase is over-expressed
in rapidly growing tissues, it can lead to poisoning which can cause severe damage to the embryo
or fetus. However, only low concentrations of anthracyclines have been found in fetal tissues and
their cytotoxic potential is unknown. Also, existing case research appears to prove that
anthracycline use during pregnancy is not toxic to the fetus, especially when not used during the
first trimester. Anthracyclines are one of the most used and effective types of chemotherapy for
breast cancer patients, and it is therefore useful to understand their effect on the fetus.
Anthracyclines such as commonly used doxorubicin do not easily cross the placenta because of
their high molecular weight. They are also substrates of the P-gp, a placental drug-transporting
glycoprotein. This glycoprotein is of great importance in limiting the fetal penetration of
potentially harmful compounds. Indeed, it has been noted that after intravenous injection of
anthracyclines only barely detectable concentrations can be found in the fetus (German N. et al
2003). It would appear that anthracyclines are not likely to be toxic, however specifically with
anthracycline-based chemotherapy, like the combination previously mentioned, the date of
administration has an effect on the risks to the fetus.
The first trimester of pregnancy is the time of organogenesis, and the fetus is therefore at
its most susceptible. When chemotherapy is administered in the first few weeks of pregnancy
there is a very high rate of spontaneous abortion. Throughout the rest of the first trimester there
is still a chance of spontaneous abortion and there is the additional risk of fetal malformations.
The risk of fetal malformations when chemotherapy is administered within the first trimester is
up to 17% as opposed to 1.3% in the two subsequent trimesters. In two different studies three
women treated during the first trimester all suffered spontaneous abortions. However, one
woman in a study from the University of Texas M.D Anderson Cancer Center was treated at 11
weeks and experienced no apparent adverse effects. As a result of these significant risk factors to
the fetus, chemotherapy is usually avoided during the first trimester (Ring A. E. et al 2005b).
Treatment with anthracycline-based chemotherapy in the second or third trimesters does
not appear to increase the risk of malformations. There are three large case study series published
about this treatment. In a U.K study 16 children of mothers exposed to anthracyclines showed no
congenital malformations. In a French survey 18 children were identified as having been exposed
and none of them presented malformations. The M.D Anderson series reported 23 children
exposed none of whom had malformations. However, when the doxorubicin dose exceeds 70
mg/mg2 per cycle it has been shown that risk of severe fetal toxicity increases 30 fold. There is
also a specific risk of cardiotoxicity associated with anthracycline toxicity later in pregnancy,
although this has not been observed in any case studies. While chemotherapy appears to be safe
during the second and third trimesters, it is advisable to stop treatments at least three weeks prior
to delivery, in order to prevent neonatal infection, neutropenia and to ensure that the mother’s
blood counts are optimal at delivery (German N. et al 2003).
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Taxanes
Among emerging therapeutic options for breast cancer are antimicrotubule agents or
taxanes such as paclitaxel, docetaxel, and vinorelbine. These drugs display a high activity against
breast cancer, and it is therefore necessary to understand how they may be used in conjunction
with pregnancy. Because these drugs are relatively new the available research is confined to case
studies, some animal data and knowledge of the nature of the drug.
Paclitaxel, docetaxel, and vinorelbine are mainly metabolized by cytochrome P450
isoforms. Because the maturation of these cytochromes mostly occurs in the first weeks of
neonatal life, fetus’ cannot metabolize these drugs and would therefore be highly susceptible to
their toxic effects if a transplacental transfer were to occur. These drugs would actually be
expected to cross the placenta because they have a relatively low molecular weight and are
highly lipophilic. However, they are highly bound to plasma proteins and plasma protein binding
is increased during pregnancy, which would potentially lead to a decreased active fraction of
these drugs. These drugs are also substrates for the Pgp which has been found in high expression
in the placenta. The placental Pgp serves to protect the fetus from a broad range of xenobiotics.
The placental Pgp therefore appears to reduce transplacental transfer of antimicrotubule agents,
making their clinical use possible in the second and third trimesters (Mir O. et al 2008).
Animal studies have shown paclitaxel and docetaxel to be toxic to the fetus. This has not
been evident in human case studies, although it is recommended to postpone the use of these
cytotoxic drugs until after the first trimester. This is firstly, to prevent spontaneous abortion, and
secondly, to prevent disruption of organogenesis which could lead to malformations (Ring A. E.
et al 2005a).
There are four reports of PABC treated with Paclitaxel. The median maternal age in the
reports is 36 years. Treatment was started during the second trimester in 3 cases and during the
third in one case. There were no documented complications, and three out of the four patients
underwent caesarean section with no reported malformations. In all cases there was a follow up
with a median of 16 months, where all the children appeared healthy and normally functioning.
However, in three cases, women treated with paclitaxel combination therapies in the last three
weeks before delivery, exhibited mild anemia in two fetus’ and one case of grade four
neutropenia.
In a literature review study there were six reports of patients with breast carcinomas who
were pregnant and treated with docetaxel. The median maternal age was 34.5 years and
docetaxel was only administered by itself in one case. Treatment was initiated during the second
trimester in three cases, and in the third trimester in three cases as well. One fetus developed
hydrocephalia only before treatment with docetaxel, but remained stable thereafter. The child
developed normally and was considered healthy at 28 months. In the other five cases no
malformations were reported. All the offspring appeared healthy with a median follow-up of
17.5 months.
There were five identifiable cases of PABC treated with vinorelbine. Vinorelbine is
generally associated with other cytotoxic drugs such as fluorouracil, csiplatin,or trastuzumab.
The advantage of using vinorelbine is primarily its lower rate of side effects, which is especially
a factor in pregnant women. The median maternal age of these five reported women was 32
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years. The drug treatment was started in the second trimester in two cases and during the third
trimester in three cases. There was no grade three or four maternal toxicity reported, and there
were no fetal malformations. All the children were reported healthy at a 23 month median follow
up (Mir O. et al 2008).
Researchers and medical practitioners have voiced the safety of using taxanes during the
second and third trimesters of pregnancy based on the data available. It is agreed that the use of
these cytotoxic drugs should be stopped for three weeks prior to delivery in order to prevent
neutropenia, and to allow the mother’s blood to regenerate its platelet counts. Further research
and analysis is required to investigate the possibility of low birth weight being associated with
the use of taxanes during pregnancy.
Conclusion
This area of study is an ongoing development and does indeed require much more
investigative research. One of the principal problems standing in the way of a clearer
understanding of placental transfer of drugs is the inability to ethically analyze live placental
tissue. In order to observe and document the way in which these drugs react within the placental
barrier one would need to inject the drug into the placental tissue: not a feasible option. When the
placenta exits the uterus after delivery the tissue dies immediately, and the activity of the drug
within its tissues would be totally different then when it is in its living state. This means that
essentially all the understanding and chemical analysis of the way drugs pass through the
placenta is conjecture. Furthermore, there is no way to test human subjects with increased doses
of these drugs to observe their potential toxicity, and animal testing has given results that do not
match human experience. Many women abort a pregnancy in the face of a serious diagnosis
causes less real life cases to be analyzed.
This last reason is the principal impetus behind this paper. The ability to treat cancer
during pregnancy is generally believed to be a modern, groundbreaking concept. In reality, the
cases of women successfully cared for while they were pregnant date back to the 1970’s. Yet still
today, the public is just beginning to understand that one need not make that most painful of
choices (Paul P. 2008). The situation presented by a breast cancer patient who is also pregnant
and wishes to continue their pregnancy, is still unusually sensitive. The idea of harming a fetus to
benefit the mother is difficult. The majority of women who do choose to continue their
pregnancy, even today, generally do so because of religious beliefs, not because they think they
and their babies will survive and be healthy. It is this public misconception that must be righted.
Women should not be allowed to feel self-doubt or nervousness, because they are opting to be
treated while continuing their pregnancy. Although research on breast cancer specifically is most
extensive, based on its higher rate of correlation with pregnancy, the examples made in this field
of cancer also apply to various other less documented cancers. It is crucial that further research
and analysis, such as the ongoing study at the MD Anderson Cancer Center, continue and are
publicized, so that unborn children need not be lost, and so that mothers should not be forced to
make an impossible choice.
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Clostridium difficile Associated Disease (CDAD)
Rivka H. Borger
Abstract
Clostridium difficile bacteria (C. difficile) are a spore-forming species of bacteria that lies
dormant in the colon, in the presence of normal intestinal flora. Due to overuse of certain antibiotics,
normal intestinal bacteria may be depleted, and combined with other
possible risk factors, allow C. difficile bacterial spores to develop into
active, infectious, and extremely resistant toxin-producing bacteria. The
toxins cause severe damage and inflammation to the intestinal wall that
can result in gastrointestinal discomfort and severe pseudomembranous
enterocolitis that must be treated with a low-risk C. difficile targeting
defense.
Figure 1 –Endoscopic
view of classic C difficile–
associated
pseudomembranous
colitis (Hull and Beck,
FMC, 2006)

Introduction

Clostridium difficile bacteria (C. difficile) are a spore-forming
species of bacteria that lie dormant in the human colon, in the presence
of normal intestinal flora. It is a commensal bacterium in a minority of the population. Smaller numbers
do not develop into significant disease. (Nation Master Encyclopedia, 2005) Most commonly due to
overuse of certain antibiotics, normal intestinal bacteria may be depleted, and through nutrient
competition, allow C. difficile bacterial spores to develop into active, infectious, and extremely resistant
toxin-producing bacterial overgrowth. The toxins cause severe damage and inflammation to the
intestinal wall resulting in a wide range of disease, but most commonly - severe enterocolitis. (Merck
Manual of Diseases, 2006)
The following discourse will detail the morphology, mechanism of infection, causes, diagnoses,
treatment, and prevention of Clostridium difficile Associated Disease.

Clostridium difficile Bacteria
Clostridium difficile is a Gram-positive anaerobic rod-shaped bacterium (Kunkel, 2006). The
species was named ‘difficile’ because it was initially hard to culture (Schroeder, MD, American Family
Physician, 2005). It belongs to the Clostridiaceae Family and genus Clostridium, which form spores.
They are motile bacteria that are numerous through nature, particularly soil. Clostridium show optimal
growth at human body temperatures, but can exist under stress in the more tolerant spore form.
(Nation Master Encyclopedia, 2005). The spores are resilient and resistant to high temperatures. Early
studies demonstrated that C. difficile could be isolated from the gastrointestinal tracts of most
neonates, identifying it as a commensal organism (Schroeder, 2005). It is found as part of the normal

Rivka H. Borger, BS ’09 graduated Touro College with her degree in Biology. She is currently a student at SUNY
Downstate Medical Center Physician Assistant Program.
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intestinal flora, and passed out with the feces of those with C. difficile spores in their intestines. (EMIS
and PIP, 2007)
Clostridium difficile produce at least two exotoxins: an enterotoxin (Toxin A) and a cytotoxin
(Toxin B). They can kill cells by altering the apical membrane permeability of the mucosal cells of the
intestinal wall, and are subsequently responsible for severe inflammation possibly leading to
enterocolitis (Gerding et al, 1995). Another toxin, binary toxin, has been identified without a role in
CDAD infection. (Nation Master Encyclopedia, 2005)
C. difficile can be passed through fecal matter and spores can lie almost anywhere in the
environment.
Clostridium difficile is considered a member of infant intestinal flora as up to 50% of infants
carry asymptomatic C. difficile in their intestinal tracts. It can grow to high numbers with elevated toxin
production with no harmful effects to
infants. (Bongaerts and Lyerly, 1996)
The normal intestinal flora
under typical conditions keep the
spores of C. difficile inactive by
outnumbering them in strength. Upon
depletion of normal flora, the dormant
inactive spores develop into active,
infectious, and resistant bacteria –
replacing the lost bacteria due to
imbalance (Merck Manual, 2006)
More recently, C. difficile
infections are more rampant – severe,
Figure 2 –Scanning electron microscopy of Clostridium
extremely
resistant,
and
easily
difficile bacteria specimen, obtained from human intestine
recurrable. (Kelly and LaMont, 2008).
It is the most frequent etiologic basis
(Wiggs, University of Waikato, 2007)
for healthcare-associated diarrhea and
a common cause of antibioticassociated diarrhea (AAD), accounting for 15-25% of all AAD episodes (Center for Disease Control and
Prevention (CDC), 2004). There have been increasing rates of CDAD-associated mortality, and this can
be due either to elevated risk population or identification of new highly virulent strains of the disease.
(Center for Disease Control and Prevention (CDC), 2005).
Additionally, two studies have proven C. difficile to be the most frequent cause of nosocomial
diarrhea. Multiple studies demonstrate the link between C. difficile and noscomial infection – many
cases arise from contamination of hospital environment (Gerding, et al, 1995).
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Clostridium difficile was first linked to disease in 1978 when it was identified as primary
causative agent of pseudomembranous colitis. It can cause disease ranging from minor gastrointestinal
discomfort
to
severe
enterocolitis, toxic megacolon, or
death.
(Sunenshine
and
McDonald, 2006)

Pathogenesis
Inflammation develops
when environmental spores
ingested infect the patient.
Spores can survive the low pH of
the gastrointestinal tract and
survive well in the anaerobic
environment of the large
intestine,
allowing
for
Figure 3 –
germination. Upon depletion of
Scanning electron microscopy of Clostridium difficile bacteria spreading on
normal intestinal flora, C. difficile
a surface
spores no longer have to
(Dave McCarthy and Annie Cavanagh, School of Pharmacy, University of
compete with other microbes,
London, 2008)
allowing them to thrive to full capacity, growing to large numbers – approximately 108 bacteria per gram
of feces. In the absence of colonic flora depletion, colonization of C. difficile will be asymptomatic and
harmless (Bongaerts and Lyerly, 1997).
Antibiotic overuse is the most common form of intestinal flora depletion. The inactive spore
from of C. difficile, once held in check by nutrient competition, becomes the dominant intestinal species.
It is transformed to its infectious form, producing toxins that inflame and damage the intestinal mucosa.
Inflammation results in hyperleukocytosis, influxing towards the colon. Colitis is variable in
degree, from mild to extremely severe. In pseudomembranous colitis, a more severe form, toxins
destroy the tissue of the intestinal epithelia until the tissue falls off, mixes with leukocytes in pus
discharge; giving the appearance of a white membranous patch on the inner intestinal lining. Some
patients infected with C. difficile do not develop colitis, but are carriers of the disease, able to transmit it
to other high-risk individuals.
Clostridium difficile bacteria’s capacity to form spores allows the organism to persist in various
areas of the environment. Additionally, the spores can be spread through fecal contamination, infecting
at-risk individuals. (EMIS and PIP, 2007) Transfer can occur via the hands of healthcare workers as well.
(Center for Disease Control, 2008). Infection used to be limited to elderly hospitalized individuals but
has grown rampant more recently. (DeNoon, 2006).
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After colonic colonization, C. difficile bacteria carry out metabolic activities similar to other
anaerobic organisms. The bacteria use some monosaccharides (i.e. glucose, fructose, mannitol,
mannose, and xylitol), but not disaccharides (i.e. lactose or sucrose), oligosaccharides, or
polysaccharides (i.e. starch). C. difficile uses substances not found free in nature, such as N-acetylglucosamine and N-acetyl-neuraminic acid, by using extracellular hydrolytic enzymes to degrade
substrates for nutrition. It can then obtain carbohydrates, amino acids, and related nutrients allowing
the bacteria to thrive in the intestine. With the depletion of normal flora, there are more nutrients
available for the bacteria to thrive on. Additionally, when a large amount of resident intestinal bacteria
are destroyed, it allows Clostridium difficile exposure to previously hidden sites of the intestine. They
can be then used for microcolony formation or receptor sites for toxins in toxigenic strains. As the
organism grows, it becomes harder for normal flora to replace it since the bacteria produces inhibitory
metabolic products, such as p-cresol, ammonia, and isocaproic acid – all inhibiting growth of normal
flora, and disturbing intestinal epithelial cell membrane function. (Bongaerts and Lyerly, 1997)
Pathogenic strains of Clostridium difficile cause enterocolitis primarily through the production of
toxin A (enterotoxin) and toxin B (cytotoxin). Both toxins are capable of stimulating proinflammatory
cytokine production implicated in pseudomembranous colitis infection. Toxins act by altering regulation
of cytoskeletal protein, leading to cell rounding and cell death. (Hull and Beck, College of Family
Physicians of Canada, 2004) The toxins cause leukocyte chemotaxis and the upregulations of
inflammatory mediators such as cytokines, producing colonic inflammation. Clinical evidence would be
a significantly elevated white blood cell count, correlating to presence of infection. Focal ulcerations
occur with increasing severity of colitis, and necrotic tissue form a membrane-like material. Thus, it is

Figure 4 – The Potent Effects on Toxin B vs. Toxin A on Intestinal Epithelium
(A)
(B)

Control, treated with buffer alone – no toxins. (B) treated with 32 nM of toxin A for 5 hours. (C) and (D)
treated with 3 nM of toxin B for 5 hours.
Exposure to toxin A shows disruptions of superficial epithelium with crypt epithelium intact. (C) treatment
with toxin B shows disruption of superficial epithelium as well. (D) shows higher magnification of colonic
damage wrought by toxin B.
(Riegler, et al, Journal of Clinical Investigation, 1995)
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called pseudomembranous colitis (Schroeder, 2005).
Animal models show toxin A induction of epithelial desquamation, increased mucosal
permeability leading to increased fluid secretion in the intestine. Toxin B has less enterotoxic effects in
animals with less correlation as a cause of disease in humans, but recent in vitro data based on human
intestinal epithelial cell testing suggests that toxin B is ten times more likely to induce colonic damage
than does toxin A. In this experiment, human intestinal mucosa was exposed to varying amounts of
both Clostridium difficile toxins A and B for five hours and subsequent damage was observed. Significant
damage was observed afterward, both electrophysiologically and morphologically. Both toxins caused
disruption to cellular F-actin and patchy damage and exfoliation was noted on superficial intestinal
epithelium. The difference lay in the potency of individual toxins. While both toxin A and toxin B caused
severe intestinal damage, toxin B disrupted the colon in a minute concentrated amount, while toxin A’s
measurement was significantly greater. This suggests the high potency of toxin B in Clostridium difficile
Associated Diseases. (Riegler et al, 1995)
In a 1999 study hypothesizing how C. difficile – induced alterations in intestinal barrier facilitate
microbial entry to the intestinal mucosa (thus facilitating microbial pathogenic shift within the intestine),
mature enterocytes were deliberately treated with varying concentrations of toxins A and B followed by
an hour incubation with an enteric microorganism such as Escherichia coli. Effects of toxins A and B
were assessed on all aspects of enterocyte function ability. Testing of the effects of toxin A and B on
mature enterocytes in vitro resulted in damage and alterations in enterocyte actin, increased bacterial
adherence and paracellular transmigration, thus correlating that Toxins A and B may facilitate bacterial
adherence and penetration of the intestinal epithelium. (Feltis, et al, 1999)
If the infecting strain is toxigenic, the patient is at risk for disease. There are other factors that
possibly affect its potency such as fimbriae (enabling bacterial adherence) and glycocalyx
(antiphagocytic capsule), both of which are produced in greater numbers in toxigenic strains of C.
difficile. Some highly virulent strains produce elevated protease levels, linked among other clostridial
pathogens to increased virulence. Other extracellular hydrolytic enzymes may play a similar role
(Bongaerts and Lyerly, 1997).
C. difficile bacteria can also have specific antibiotic-resistant genes, targeting specific
antimicrobial agents through unique bacterial physiology and biochemistry. An example of this would
be the ermB gene, encoding a 23S ribosomal methylase that causes resistance to macrolide-lincosamidestreptogrammin (MLS) antibiotics. This marker was noted in several cases of C. difficile after use of
Clindamycin, a lincosamide derivative. (Hull and Beck, 2004).
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Another strain of Clostridium difficile bacteria has been identified relatively recently, named
North American pulsed-field gel electrophoresis type 1 (NAP 1), causing several outbreaks in North
America and Europe. It is resistant to both gatifloxacin and moxifloxacin antibiotics (both of the
fluoroquinolone antibiotic group), unlike other strains previously designated. NAP 1 produces 16 times
greater toxin A and 23 times greater toxin B than other strains do, possibly related to a deletion in a
negative regulatory gene. It also produces a third toxin, binary toxin, whose purpose has not been
deemed significant yet. (Sunenshine and McDonald, 2006). This new strain has become the more
dominant strain, due to the high rate of mutation. It is highly virulent and has raised C. difficile-related
death rates by 35% yearly (DeNoon and Chang, 2008). Additionally, resistance to fluoroquinolone
antibiotics gives the NAP-1 strain with the ability to spread more rapidly among healthcare
environments where those antimicrobial agents are most frequently used. (Center for Disease Control
and Prevention (CDC) 2005)

Causes and Risk Factors
The primary cause of infection is due to
antimicrobial therapy, more prevalent in
certain antibiotic groups.
Antimicrobial agents that target
anaerobic bacteria are potentially more lethal,
possibly because they alter intestinal flora and
microbial ecology. (Gerding et al, 1995)
Almost all antimicrobial agents except
for aminoglycosides are associated with
Clostridium difficile infection (Sunenshine and
(Cleveland Clinic, 2006)
McDonald, Cleveland Clinic Journal of Medicine,
2006). Clindamycin has been identified as a
targeting agent, confirmed by ermB gene isolation, encoding methylase enzyme causing antibiotic
resistance to lancosamides (Clindamycin belonging to that family). (Hull and Beck, College of Family
Physicians of Canada, 2005). Other common high-risk antibiotics are broad spectrum penicillins, second
and third generation cephalosporins, erythromycin, sulfonamides, chloramphenicol, tetracycline, and
fluoroquinolones. Fluoroquinolones in particular were isolated in a cohort study as the predominant
risk factor for CDAD in a specific epidemic in Quebec 2003-4 (Pepin et al, 2005). It is most commonly
due to oral antibiotics but can also occur due to intravenous or intramuscular antibiotics. (Merck
Manual, 2006). Other antimicrobial agents, including antiviral and antifungal drugs increase the risk as
well (Mayo Clinic 2006). Risk more than doubles with greater than three days of antimicrobial therapy.
Figure 5– marked exudates protruding through
mucosal ulcerations

Reduced-risk
(Schroeder, 2005).

antibiotics

include

vancomycin,

metronidazole,

and

antipseudomonals.
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The critical point of infection is right after normal intestinal flora depletion before replenishing
(Bongaerts and Lyerly, 1997).
Other drugs may increase susceptibility as well, such as drugs and conditions that decrease
gastric acidity. Over the counter antacids and proton pump inhibitors such as aciphex, prevacid, and
related drugs would put a patient at higher risk (Merck Manual, 2006). Proton pump inhibitor (PPI)
utilization is associated with upper gastrointestinal tract colonization and altering of intestinal flora.
Decreased gastric acidity is a known risk factor for infectious diarrheal illnesses. Since Clostridium
difficile bacteria thrive on higher gastric pH levels, decreased gastric acidity may also pose a risk factor
for CDAD. This is supported by CDAD cases reported from patients receiving Helicobactor pylori
treatment – combining proton pump inhibitors with antibiotics. A study comparing rate of C. difficile
infection in patients undergoing gastric acid suppressive therapy with those who did not, with PPI usage
increasing the risk significantly. (Dial et al, CMAJ, 2004). Two case-controlled studies conducted over ten
years showed the increase in rate of Clostridium difficile infection due to PPI usage and H2 blockers.
(Dial, et al, JAMA, 2005).
Additional risk factors included use of non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen. Being methicillin-resistant Staphylococcus aureus positive increases susceptibility in hospital
patients. (Dial, et al, JAMA, 2005).
Exposure to Clostridium difficile can occur through a variety of methods. Transfer of pathogenic
organisms is highly prevalent via the hands of health-care workers and is considered the most likely
mechanism. (Centers for Disease Control and Prevention (CDC) 2007).
Other risk factors include underlying illness, weakened immune system, recent hospitalization,
residency in long-term care facilities, recent surgery – primarily abdominal/gastrointestinal, chronic
colon disease such as inflammatory bowel disease or colon cancer. Additionally, previous infection with
Clostridium difficile increases patient susceptibility to reinfection. (Mayo Clinic, 2006). Highest risk
patients are those with recent immunosuppressive therapy or recent surgical procedures, partly due to
patients’ inability to generate IgG antibody immune response against Clostridium difficile toxin A. IgG
immune response ability does not protect against colonization but can decrease risk of morbidity,
mortality, or recurrence with C. difficile infection (Schroeder, 2005).
Cancer chemotherapy and increased age and severity of underlying illness are other possible risk
factors (Hull and Beck, 2005)

Clinical Manifestations of Enterocolitis
More commonly, patients experience colonization rather than disease. Such patients exhibit no
clinical symptoms even though they would test positive for C. difficile organism and/or toxins. Other
times, patients contract Clostridium difficile-Associated Disease (CDAD) and exhibit clinical symptoms
(Centers for Disease Control and Prevention, 2005).
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Common symptoms for Clostridium difficile infection are watery diarrhea (characterized by at
least three bowel movements daily for more than two days but usually ten or more), abdominal
cramping and tenderness, nausea, loss of appetite, and fever of up to 104 – 105 degrees F. (Centers for
Disease Control and Prevention, 2004). It is also possible to have an abnormal heartbeat (Healthwise,
2006). Other symptoms include blood or pus in the stool, dehydration, and weight loss (Mayo Clinic,
2006). Watery diarrhea is the most common symptom of CDAD in children (Infectious Diseases and
Immunization Committee, 2000). Rarely are symptoms manifested outside the gastrointestinal tract, but
can include cellulitis, bacteremia, visceral abscess formation, and reactive arthritis. A common indicator
would be leukocytosis with a white blood cell count greater than 30.0 x109/L (Hull and Beck, 2004).
Symptoms can appear immediately after or during antimicrobial therapy, but can often appear
several weeks after completing all antibiotics. This was evidenced in a study of cancer outpatients
diagnosed with CDAD where the median interval (range 2-60 days) from discharge to infection was 20.3
days – a 3 week delay (Sunenshine and McDonald, 2006).
Range of disease can vary in different individuals from asymptomatic colonization to severe
fulminant pseudomembranous colitis.
Many cases are mild. Such patients develop mild to moderate watery diarrhea with abdominal
cramping and nausea, similar to ordinary viral gastroenteritis. They may last a short duration to several
weeks but usually improve without treatment (EMIS and PIP, 2007). Systemic symptoms are usually

Figure 6 –
Pathogenesis of
Clostridium difficile
Infection (Adapted
from “Clostridium
difficile –Associated
Diarrhea”, Schroeder,
2005)
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absent and disease would only be considered due to abdominal tenderness upon physical examination
(Sunenshine and McDonald, 2006). They may also include low grade leukocytosis and tenesmus – a
sudden urge to evacuate the rectum (Hull and Beck, 2004).
Moderate infectious symptoms include leukemoid reaction – a stress response to disease with
an increased leukocyte count of approximately 50.0 x109/L, fever, dehydration, nausea, vomiting, and
abdominal tenderness. Hull and Beck, 2004).
The severest cases present with dehydration and electrolyte disturbance, severe bloody
diarrhea, fever, and abdominal pain and cramping (EMIS and PIP, 2007). It may lead to sepsis and shock,
acidosis (increased acidity of blood plasma), tachycardia, multisystem organ failure including kidney
failure (due to rapid dehydration), hypoalbuminemia, paralytic ileus, ascites (fluid accumulation in the
peritoneal cavity), acute abdomen – colonic perforation, toxic megacolon (toxic colitis with dilatation),
and death. Endoscopic evaluation of the colon will show pseudomembraneous white patches or lesions

Figure 7 – (L) Image of normal cecum
(R) Image of pseudomembranes formed from Clostridium difficile overgrowth of
cecum.
(Adapted from Johnson, Medical Microbiology, 2009)
with erythema and edema. The lesions are yellow plaques 2-10 mm in diameter with interposed normal
intestinal mucosa (Hull and Beck, 2004). Should a patient develop paralytic ileus or toxic megacolon, it
may actually lead to a decrease in diarrheal episodes. (Sunenshine and McDonald, 2006). Toxic
megacolon is rare but has been documented in several cases, leading to a mortality rate of 33% for
those who develop it. A critical factor in survival would be early diagnosis of Clostridium difficileassociated pseudomembranous colitis (Cone and Wetzel, 1982).
Diagnosis
Detailed history is the first step to proper diagnosis. Patients are screened for recent antibiotic
usage, abdominal pain, diarrhea, and related symptoms. Doctors may still test without presence of
diarrhea since in rare instances C. difficile bacteria can cause abdominal pain and tenderness without
diarrhea (MedicineNet, 2008). C. difficile is also suspected when diarrhea develops during or soon after
hospitalization (EMIS and PIP, 2007).
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Treating without diagnostic laboratory basis is not indicated, especially since only 30% of
hospitalized patients with diarrhea have CDAD, even during epidemics. There are some exceptions for
which empiric therapy would be necessary – including severely ill or rapidly deteriorating high-risk
patients (Sunenshine and McDonald, 2006).
Patients with CDAD often have leukocytosis with strong elevation in severe enterocolitis.
Physicians may screen leukocyte count as well as for white blood cell presence in the stool.
Confirmation of those two tests proves positive for colitis and would need more testing to diagnose
CDAD (MedicineNet, 2008). Stool leukocyte measurement may have limited diagnostic accuracy
(Nation Master Encyclopedia, 2005). A sudden rise in the leukocyte count to between 30-50x109/L cells
combined with severe bandemia (immature white blood cells) is an indicator of fulminant colitis.
Patients should be monitored for leukemoid reaction as shock can progress very quickly (Schroeder,
2005).
Stool assay for Clostridium difficile is a routine method. It is not always reliable as it sometimes
produces false-negatives (Mayo Clinic, 2006). Additionally, although the most sensitive test possible, it
can also cause false-positives due to the available nontoxigenic strains. It must grow 48-96 hours anaerobically
for proper results. (Centers for Disease Control and
Prevention (CDC), 2005). It has an overall sensitivity of
95% but has a low specificity, necessitating toxicity
testing (Canadian Paediatric Society, Paediatrics & Child
Health, 2000). It is not specific for pathogenic toxinproducing strains of Clostridium difficile and is not as
clinically helpful (Schroeder, American Family Physician,
2005). It is the least chosen method of testing in
hospitals due to cost and length of procedure. It does
Figure 8 – anaerobic culture of
however have an advantage of lending itself to molecular
Clostridium difficile bacteria on
typing of strains, useful in a C. difficile outbreak
Cycloserin-Cefoxitin Fructose Agar
(Anaerobe Systems, CA)
(Sunenshine and McDonald, 2006).
(Adapted from Johnson, Medical
Antigen detection for C. difficile are rapid tests
Microbiology,
2009)
completed in less than an hour, used to detect presence of C. difficile antigen by latex agglutination or
immunochromatographicassays. It must be combined with toxin testing for diagnostic confirmation
(Centers for Disease Control and Prevention (CDC), 2005).
Toxin testing includes both enzyme immunoassay and tissue culture cytotoxicity.
Enzyme immunoassay detects toxins A, B, or both together. It uses monoclonal antibodies to
detect toxin (Hull and Beck, 2004). Assay is completed same-day but is less sensitive than tissue culture
cytotoxicity assay (Centers for Disease Control and Prevention (CDC), 2005). Enzyme-linked
Immunoabsorbant Assay (ELISA) has a sensitivity rate of 63-99% and a specificity of 93-100%. Experts
recommend sending as many as 3 samples to rule out disease if patients receive negative result, but
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may not be necessary as much with ELISA (Nation Master Encyclopedia, 2005).
The majority of
combination enzyme immunoassays have a sensitivity of 85-95%. It should not be used as an indicator
of response to therapy since results remain positive for extended duration in 25% of successfully treated
patients (Schroeder, 2005).
Tissue culture cytotoxicity tests only for presence of toxin B. It is called the ‘gold standard’ toxin
bioassay (Canadian Paediatric Society, Paediatrics & Child Health, 2000). It requires 24-48 hours for a
final result and is very sensitive for C. difficile (Centers for Disease Control and Prevention (CDC), 2005).
Organisms are cultured on selective medium and tested for toxin production and cytopathic effect in cell
culture. It is the most sensitive and specific test although it is slow and labor-intensive (Nation Master
Encyclopedia, 2005). Due to its high specificity and sensitivity, one should be cautious for false results
(Canadian Paediatric Society, 2000).
C. difficile toxin is very unstable. Toxin degrades at room temperature and may not be
detectable 2 hours after collection of stool. False-negative results are prevalent due to delayed testing
or lack of refrigeration.
Stool lactoferrin levels can also be a diagnostic test but has limited diagnostic accuracy as well
(Nation Master Encyclopedia, 2005). Other rapid testing such as Immunocard (Meridian Diagnostics) is
highly specific but has poor sensitivity with up to 20% false negative results (Canadian Paediatric Society,
2000). Latex agglutination-based assays recognize enzyme glutamate dehydrogenase but do not have
sensitivity (Hull and Beck, 2004). Polymerase chain reaction (PCR) detects toxigenic C. difficile.
Amplification of a gene portion of either toxin A, toxin B, or a combination of the two genes is
performed. PCR can be conducted on the specimen organisms for presence of toxins that match with
the reading of the known toxins. One testing conducted (Kato et al) amplified only toxin A from C.
difficile. Others had similar or less success. It is not as sensitive as other testing methods (Gerding et al,
1995).
Colon examination is used to confirm diagnosis of Clostridium difficile. Patients undergo
sigmoidoscopy or colonoscopy to screen for presence
of inflammation and pseudomembrane appearance,
both suggesting CDAD (Mayo Clinic, 2006). It should,
however, be reserved for when a patient’s condition
needs rapid diagnosis, to rule out other diagnoses, or
when clinical suspicion is high despite negative
results.
Colonoscopy can detect more than a
sigmoidoscopy since it examines the whole colon
where C. difficile can encompass, rather than just the
sigmoid colon (Hull and Beck, 2004).
Imaging tests such as CT scans provide
detailed images of the colon. Scans can show
thickening of the colon wall, common in
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pseudomembranous colitis (Mayo Clinic, 2006). In conjunction with the clinical history, presence of
ascites, colon wall thickening, or dilation can predict severity of enterocolitis (Schroeder, 2005).
Treatment
No treatment is necessary for colonization without symptomology.
present with diagnosis confirmed, there are different treatment options.

Should symptoms be

If at all possible, the disease-causing antibiotics should be stopped. This alone can allow normal
intestinal flora to regenerate. Overgrowth of C. difficile would be reduced with less symptoms ensuing.
For mild to moderate diarrhea and other symptoms, cessation of antimicrobial therapy may be the only
necessary cause of treatment (EMIS and PIP, 2007). CDAD typically resolves in 23% of cases upon
removal from the antimicrobial treatment (Centers for Disease Control and Prevention (CDC), 2005).
Fluids may be given to prevent dehydration and restore electrolyte balance in the blood
(Healthwise, 2006).
For severe cases of diarrhea or diagnosed colitis, patients will be treated with an antibiotic that
eradicates C. difficile organisms, usually Vancomycin (Vancocin) or Metranidazole (Flagyl), for ten days.
In a study of 189 patients with CDAD, 97% responded to initial antibiotic therapy (Sunenshine and
McDonald, Cleveland Clinic Journal of Medicine, 2006). Symptoms should subside within 2-3 days. The
antibiotics can also prevent perforation of the colon if treated in time (EMIS and PIP, 2007). Drugs are
usually effective with few side effects (Centers for Disease Control and Prevention (CDC), 2007). In
severe cases, intravenous medications may need to be administered (Robert Michael Educational
Institute, 2007). Both Vancomycin and Metranidazole are equally effective. Physicians may choose to
prescribe Metranidazole first since it is far less expensive than Vancomycin. Vancomycin is reserved for
patients who are allergic to Metronidazole, do not respond to it, or have side effects. Other physicians
choose Vancomycin primarily for severe colitis since it can achieve higher antibiotic levels in the colon
and can theoretically be more effective at eradicating bacteria there with more area specificity
(MedicineNet, 2008).
It can, however, contribute to the growth of antibiotic-resistant bacteria.
Metranidazole can not be used for women who are pregnant or breastfeeding. Both antibiotics kill only
the active infectious form of C. difficile, not the tougher spores. Since spores are resistant and remain in
the body, infection can return, requiring further treatment (Mayo Clinic, 2006). For those unable to
tolerate oral medication, IV Metronidazole is used since it is excreted in the intestine (Canadian
Paediatric Society, 2000).
Other drug regimens compared in randomized therapeutic trials for CDAD with good results are
Bacitracin, Teicoplanin, and Colestipol. Cure rates in Bacitracin are somewhat lower than Vancomycin,
and it should be treated as a secondary agent in treatment. Colestipol is even lower than Bacitracin
(Gerding et al, 1995).
Some physicians prescribe supplementary probiotics to restore normal intestinal flora. A
natural yeast, Saccharomyces boulardii, and Lactobacillus species has proven effective in treating C.
difficile infections together with antibiotic (Sunenshine and McDonald, 2006).
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Antidiarrheal medications such as loperamide, diphenoxylate, and bismuth compounds are
contraindicated and can worsen the course of pseudomembranous colitis. Slowing of fecal transit tie
can possibly extend toxin-associated damage. Cholestyramine, usually used to lower cholesterol, is
more effective in slowing bowel motility without causing more damage (Nation Master Encyclopedia,
2005).
If the disease causes fulminant colitis, surgical resection of the colon may be needed, especially
with colon perforation (EMIS and PIP, 2007).
In e cases causing severe pain, organ failure, or
inflammation of abdominal wall lining, surgical removal may be the only option (Mayo Clinic, 2006).
Surgery should be considered especially if initial treatment does not resolve the disease and symptoms
progress rapidly. Still, treatment should not be considered failure before 6-7 days of therapy
(Sunenshine and McDonald, 2006). At times, a patient may relapse with recurring episodes of CDAD.
Multiple courses of antibiotics may be needed. Probiotic treatment may be helpful for this (Canadian
Paediatric Society, 2000). Approximately 15-35% of patients have recurrent disease. This could be from
reinfection or germination from residual spores. The most likely reason for relapse is that C. difficile had
not been completely eradicated during treatment (MedicineNet, 2008).
There is no evidence that
recurring infections cause more severe disease (Hull and Beck, College of Family Physicians of Canada,
2004). Another possible reason leading to relapse is the body’s inadequate production of antibodies
against the bacterial toxins (MedicineNet, 2008). Fecal enemas, however, are difficult to perform and
there is an increased risk of transmitting retroviruses or other infectious diseases (Schroeder, 2005).
Fecal bacteriotherapy, sometimes commonly called a “stool transplant”, has its basis in
probiotic therapy research. Normal intestinal bacterial flora obtained from the feces of a healthy
individual is infused through the intestine of the patient in an effort to restore normal flora balance,
decreasing the strength of the C. difficile organisms and lessen likelihood of recurrence. This treatment
is usually used for people with recurring episodes of disease. It has a success rate of nearly 95% (Nation

Figure 10 – Laboratory preparation of stool for fecal bacteriotherapy
(The Medical Post, 2009)
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Master Encyclopedia, 2005). Anaerobic bacteria and fecal rectal enemas are usually obtained from
healthy relatives to promote better acceptance by the patient’s body. They are instilled rectally and can
restore colonic flora (Hull and Beck, 2004).
For patients with multiple relapses possibly due to antibody deficiency, passive immunizations
with human gammaglobulin can be administered intravenously. This will grant them large amounts of
antibodies to eradicate the disease. Additional work is in progress to promote active vaccination against
C. difficile toxins, to increase patient levels of antibodies. (MedicineNet, 2008)

Prevention
Most importantly, avoid using antibiotics unless absolutely necessary. Antibiotics will not
eradicate viral illnesses, yet they are still used for that purpose several times annually. Even some
common bacterial ailments like bronchitis and ear infections can be treated without antibiotics (Mayo
Clinic, 2006). In particular, restriction of Clindamycin has been shown to decrease incident of CDAD
(Schroeder, 2005).
If antibiotics are necessary, have the physician prescribe from a narrow-spectrum range to be
taken in the shortest amount of time possible for least likelihood of disrupting intestinal flora (Mayo
Clinic, 2006).
Use probiotic supplements – yogurt with live cultures, acidophilus, and similar during the
antibiotic course. However, only Saccharomyces boulardii is proven effective against C. difficile
specifically (Mayo Clinic, 2006). Lactobacilli have been proven effective against antibiotic-associated
diarrhea, but not necessarily that caused by Clostridium difficile.
Any patient with CDAD, even asymptomatically colonized, can transmit the disease to others.
Only those on antibiotics, hospitalized, or with other prevailing risk factors are most likely to get ill. To
reduce transmission, wash hands carefully especially after restroom use and before eating. Regularly
clean surfaces used routinely, such as kitchens and bathrooms (Centers for Disease Control and
Prevention (CDC), 2007). Ideally, a mixture of bleach and water should be used – with a ratio of 1:10
bleach to water. Patients with diarrhea should try to avoid using the same toilet other family members
use unless it can be washed out each time with the bleach and water mixture (Robert Michael 2007).
Hospitalized patients known or suspected to have the disease should be treated using the 1994
Hospital Infection Control Practices Advisory Committee (HICPAC) Guideline for Isolation Precautions in
Hospitals recommended contact precautions (Sunenshine and McDonald, Cleveland Clinic Journal of
Medicine, 2006). Place those patients in private rooms if possible, or with other patients with C. difficileassociated disease. Use gloves and gowns to prevent transmission and wash hands with alcohol-based
hand rubs or soap and water. Soap and water alone is best for direct care of CDAD patients as it is more
effective against spore-forming bacteria. Dedicate equipment to them wherever possible. (Division of
Healthcare Quality Promotion (DHQP), 2005) Visitors should wash hands with soap and warm water
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before entering and leaving a CDAD patient’s room. (Mayo Clinic, 2006). One hospital reported a 60%
decrease in CDAD after instituting more stringent precautions (Sunenshine and McDonald, 2006).

Summary
Clostridium difficile-Associated Disease (CDAD) may be a slightly rare disease but with
devastating effects. Due to depletion of normal intestinal flora in conjunction with other risk factors
including immunocompromised state or recent hospitalization, dormant resistant spores transform to
virulent possibly toxigenic infectious form of bacteria that can multiply rapidly. Although broad in
arrange of symptomology, the possibility of leading to severe pseudomembranous colitis with risk of
colonic perforation, toxic megacolon, or death exists. Treatment is possible – with expensive drugs and
other measures, but not without the possibility of relapse, even numerous reoccurrences. Prevention
must be taken to avoid susceptibility to this virulent and damaging organism altogether, by maintaining
proper precautions. Should someone already have the disease, proper care must be implemented to
ensure no further transmission as spores can be spread through contact and fecal-oral methods.
Research is still preliminary for other treatments, including vaccination against C. difficile toxins. With
proper prevention and treatment, and increase in patient antibodies to target the organism, even in the
absence of normal intestinal flora, Clostridium difficile-Associated Disease can be eradicated.
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Aspartame: A sweet toxin?
Atara Rena Degani
Abstract
L-aspartyl-L-phenylalanyl-methyl ester, commonly known as aspartame, is one of the most
widely used and controversial sweeteners. Many have questioned the safety of this chemical, concerned
that it may be neurotoxic and carcinogenic. Numerous studies have been conducted on the three basic
constituents of aspartame: aspartic acid, phenylalanine and methanol; scientists have tried to determine
whether the ingestion of aspartame will cause a significant increase in blood plasma levels of these
chemicals, and whether such an increase is dangerous. This review analyzes various studies conducted
on the health effects of these metabolitic byproducts of aspartame.

Introduction
Consumers were thrilled when aspartame was introduced to the market. Since this artificial
sweetener’s safety was approved, it has found its way into over 6,000 products, including soft drinks,
chewing gum, hot chocolate, candy, desserts, sweeteners, and yogurt. Sold commercially under names
such as Nutra-Sweet, Equal and Canderel, aspartame is two hundred times sweeter than sucrose.
Although it has the same number of calories per gram as sucrose, people generally use less of it,
consuming fewer calories (Soffritti et al. 2006).
The discovery of aspartame was accidental. In 1965, James M. Schlatter discovered this chemical
as he was trying to produce an anti-ulcer drug candidate for G.D. Searle & Company. Some aspartame
spilled on his hand, yet he did not wash it off, believing that it was not toxic. He came to recognize its
sweetness when he licked his fingers in order to pick up a weighing paper. Despite its unintentional
discovery, aspartame has had a profound impact on the dieting habits, and it is one of the most widely
used artificial sweeteners in the world (Sofffritti et al., 2007).
Aspartame’s unique formula helps obese maintain their weight loss programs and allows
diabetics to enjoy exceptional dishes within their dietary restrictions (Butchko et al. 2002). In the United
States, the acceptable daily intake (ADI) of aspartame is 50 mg/kg body weight. Consumption by the
general population ranges from 2 to 3 mg/kg body wt, and the average consumption by children and
women of child bearing age has been estimated at 2.5-5.0 mg/kg bw/day (Soffriti et al., 2007).
Extensive research was done on the safety of aspartame before it entered the market. Various
studies were conducted with a number of human populations in order to determine its safety; research
was done on a range of ages and on various segments of society, such as obese individuals, diabetics,
and individuals heterozygous for the genetic disease phenylketonuria (Butchko et al. 2002). While many
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exists about its safety. Numerous anecdotal reports were released subsequent to aspartam’s approval
describing the adverse health affects associated with it. Written complaints include that of dizziness,
visual impairment, disorientation, ear buzzing, tunnel vision, loss of equilibrium, severe muscle aches,
numbing of extremities, increased blood pressure, retinal hemorrhaging and depression (Monte 1984).
Even more serious is the startling rise in brain tumor rates since the introduction of aspartame to the
market (Olney et al. 1996).

FDA Approval
Aspartame was approved by the FDA for use in solid foods in 1981, in soft drinks in 1983, and as
a general sweetener in 1996. The FDA denied approval of this sweetener for eight years before allowing
it on the market since researchers had discovered that the ingestion of aspartame yielded toxic effects.
A Public Board of Inquiry (PBOI) convened in 1980 to review the research of G.D. Searle and Company
and they denied approval of the chemical due to lack of sufficient evidence proving that aspartame did
not cause cancer. The FDA commissioner, Arthur Hull Hayes, established another PBOI in 1981. This
board did not reach a consensus regarding the chemical, yet the commissioner overruled his own board
of inquiry and approved the food additive. Conspiracy theories brew because Hayes left the FDA in 1983
to join the public relations department of Searle (Whitmore 1996). The validity of the FDA’s approval is
further questioned when the research conducted on aspartame is analyzed. One is compelled to
question the design efficiency of many studies when one notes that 100% of the 74 industry-funded
studies found no problem, while 83 out of 90 non-industry funded studies found one or more problem
with aspartame (Warner 2006).
Structure and Components of Aspartame
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Aspartame is a dipeptide which has the formula L-aspartyl-L-phenylalanyl-methyl ester (Maher
and Wurtman 1987). Upon ingestion, aspartame is metabolized in the gastric tracts to its three
constituents: aspartate, phenylalanine, and methanol. These components proceed to be transformed
into other products. Aspartate is transformed into alanine and oxaloacetate; phenylalanine is
transformed into tyrosine, phenylethylamine and phenylpyruvate, and methanol is transformed into
formaldehyde which later forms formic acid (Soffritti et al. 2006). While these components are
commonly digested, concerns have been raised about their safety when they are metabolized after
aspartame ingestion.

Aspartate
Aspartate is an extremely common, non-essential amino acid. It is usually rapidly metabolized by
the body and subsequently incorporated into proteins and utilized for energy. This amino acid is found
in large concentrations in natural products; 100g of chicken yields 2600 mg of aspartate whereas a 355
ml beverage sweetened 100% with aspartame only provides 70 mg of aspartate. Furthermore, a glass of
no-fat milk provides 13 times as much aspartic acid as a beverage sweetened 100% with aspartame
(Monte 1984).
While aspartate is not toxic when absorbed, even in large quantities, from natural foods, it may
be harmful to the body when it is absorbed after the consumption of aspartame. Blood component
levels of amino acids such as aspartate and phenylalanine will not rise significantly after the digestion of
natural proteins. Due to their quaternary structures, natural proteins are digested slowly and enzymes
must catalyze the protein and release numerous amino acids before phenylalanine or aspartate can be
released. On the other hand, the digestion of aspartame can raise component blood levels rapidly since
the chemical only requires the breakage of two bonds for absorption (Monte 1984).
When aspartate it is absorbed in excess, it can wreak significant damage on the body. Daabes
and co-workers (1985) determined that plasma levels of aspartate and glutamate which exceeded 110
numol/dl, induce hypothalamic neuronal necrosis in neonatal rodents. Later, Olney and Sharpe (1969)
conducted a similar experiment on non-human primates. They delivered large boluses of glutamate, a
similar dicarboxylic amino acid, and found that it led to hypothalamic neuronal necrosis. Furthermore,
scientists have found that high plasma levels of this amino acid cause endocrine disorders in mammals,
leading to the release of pituitary gonadotropins and prolactin in the rhesus monkey and noticeably
elevated plasma levels of luteinizing hormones and testosterone in rats (Monte 1984).
Experiments have determined that aspartame alone will not elevate plasma aspartate levels for
an extended time period. However, concerns have been raised about the ability of aspartame to spike
plasma aspartate levels when it is ingested in conjunction with mono sodium glutamate (MSG). The
ingestion of MSG has been known to cause adverse symptoms in individuals due to the substance’s
neuroexcitatory activity (Reif-Lehrer 1976). Since both aspartate and glutamate are structurally similar,
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and pose a threat of neurotoxicity at high dosages, Olney (1982) has suggested that consuming
aspartame along with foods which contain MSG leads to a risk of toxicity and of focal brain lesions.
However, Stegink and coworkers (1983) conducted numerous studies and discovered that while MSG
consumption will lead to a significant increase in glutamate aspartate concentrations when consumed
alone, the addition of aspartame to MSG will not cause any further increase in dicarboxylic amino acid
levels. Thus, they concluded that is impossible for humans to ever consume enough MSG and aspartame
to raise plasma concentrations to those associated with rat neurotoxicity.

Phenylalanine
Phenylalanine is an amino acid which is beneficial for one’s health, and can be found in proteincontaining foods such as non-fat milk and fruit juice. This amino acid can be lethal to those who suffer
from phenylketonuria (PKU), a rare genetic disease. The diets of phenylketonurics are extremely
restricted from shortly after birth in order to avoid the risks of mental retardation or various degrees of
cognitive impairment (Butchko et al. 2002). However, phenylalanine is not only dangerous for
phenylketonurics; spikes in plasma phenylalanine levels can be toxic due to the body’s method of uptake
of this amino acid.
Upon ingestion, phenylalanine is absorbed across the gastrointestinal mucosa into portal
circulation. Most dietary phenylalanine goes unchanged into systemic circulation and is taken up across
the blood-brain barrier and into the central nervous system via a transport system that is specific for
large neutral amino acids (LNAA). The amount of amino acids which enter and leave the brain is
determined by the concentration of the LNAA and their specific affinity constants to the carrier system
(Fernstrom and Wurtman 1997). The danger of spiked plasma levels of phenylalanine lies in the fact that
it will interfere with the availability of tyrosine and tryptophan. Consequently, phenylalanine will act as a
competitive inhibitor of the enzyme tyrosine hydroxylase. This, subsequently, lowers the concentration
of brain catecholamine and serotonin, which, in turn, mediates neurological changes and induces
seizures (Maher and Wurtman 1987).
Some researchers suggest that aspartame ingestion poses a risk because it provides
phenylalanine without other LNAA. Consequently, upon being metabolized there will be an increased
phenylalanine uptake by the brain causing the aforementioned problems (Maher and Wurtman 1987).
However, other scientists, such as Stegink and coworkers (1987), found that this is not the case. In their
studies, they found that the changes in phenylalanine LNAA in normal subjects was no greater than
those occurring under normal dietary conditions. This idea was reinforced in a study conducted by
Koeppe and coworkers (1991). In this study, positron emission tomography was used in order to observe
the effects of elevated plasma phenylalanine levels after the consumption of large boluses of
aspartame. An 11.5% decrease in amino acid transport rate constant was observed along with a 6%
decrease in tissue distribution volume of aminocyclohexanecarboxylate. Thus, under normal dietary use,
aspartame is unlikely to cause changes in brain amino acid uptake which would be measurable by PET.
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Despite the fact that many scientists do not believe aspartame will negatively affect the brain’s
uptake of amino acids, several adverse side effects are observed after phenylalanine’s digestion. Many
individuals have reported that they have suffered from neurological or behavioral reactions in
association with aspartame consumption, a symptom which can be linked to increased phenylalanine
levels (Maher and Wurtman 1987). Furthermore, Walton and coworkers (1993) found that individuals
with a history of mood disorders, such as depression and bipolar, exhibited stronger symptoms after
consuming aspartame. They hypothesize that the disorders are exacerbated by aspartame’s
phenylalanine component which upsets the balance of neurotransmitters.
Another concern raised regarding phenylalanine is its ability to induce seizures. In one study,
mice were given dosages in which phenylalanine levels rose above tyrosine levels, a phenomenon which
will occur after any aspartame dose in humans. Subsequently, the mice were introduced to
epileptogenic drugs, inhaled fluorotyl or electro convulsive drugs; the frequency of seizures following
these treatments was greatly increased due to increased plasma phenylalanine levels (Maher and
Wurtman 1987). Some researchers disagree with these findings. In research done by Dailey and
coworkers (1989), acute oral doses of aspartame, ranging from 0 – 2500 mg/kg were administered to
CD-1 mice. Increases in phenylalanine and tyrosine and modest reduction in brain serotonin and 5hydroxinol acetic acid were observed. However, these changes were insufficient to cause functional
deficits which might have the capacity to facilitate pentyl enterazol-induced seizures. Thus scientists
have not been able to conclusively determine whether or not aspartame will induce seizures.

Methanol
Methanol, or wood alcohol, is the simplest alcohol with the formula CH3OH. Occurring naturally
in fruit juices and alcohol, it can be found in considerable quantities in a daily diet; for instance, tomato
juice provides six times more methanol than an equivalent amount of beverage sweetened 100% with
aspartame (Butchko et al. 2002). Ten percent of aspartame’s weight is absorbed as methanol. This
chemical is released in the small intestine after chymotrypsin hydrolyzes the methyl group of the
dipeptide.
It is transformed later into formaldehyde and formic acid., both toxic metabolites.
Absorption of methanol increases if it is ingested as free methanol, such as in heated foods and soft
drinks (Monte 1984).
The dangers of methanol consumption via aspartame have been raised over the years.
Methanol does not cause toxicity when consumed in wines and juices because of the beverages’ natural
protective features. For instance, juices and wines contain high ethanol to methanol ratios; some
neutral spirits contain 200 molecule of ethanol per molecule of methanol and orange juice contains 0.8
mg/L of methanol and 380 mg/L of ethanol. This has a protective effect since ethanol slows the rate of
methanol being transformed into formaldehyde, thereby allowing the body to excrete methanol in
breath and in urine. Juices have an added protection since they have high osmolality and an average
caloric density of 500 kcal/L, which also puts definite limits on consumption level rates of methanol.
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Since aspartame is not limited by calories or osmolarity, daily methanol levels may rise to
unprecedented levels, and may prove to be a cumulative toxin (Monte 1984).
One of the key concerns about methanol is its production of the methyl alcohol syndrome. This
toxicity is found only in humans because man has limited biochemical pathways for detoxification. For
twelve to eighteen hours after the methanol consumption there is a latent period, followed by severe
acidosis which is caused, in part, by formic acid formation. Patients complain of confusion, lethargy, and
impairment of articulation, and may also suffer from back pain, vertigo, abdominal pain, labored
breathing, leg cramps, and visual loss. There are also fatal cases in which the liver kidney and heart show
parenchymal degeneration and the lungs display desquamation of epithelium, edema, emphysema,
congestion, and bronchial pneumonia (Monte 1984).
The danger of methanol is rooted in its production of formaldehyde, a known carcinogen.
Formaldehyde has been proven to form squamous-cell carcinomas when inhaled by experimental
animals. It reacts with DNA causing irreversible denaturation and can interfere with DNA replication,
thus causing mutations (Monte 1984). Studies have verified that formaldehyde accumulates after the
consumption of aspartame. Trocho and coworkers (1998) synthesized aspartame using a methanol
group which had radioactive C-14 and fed it to mice. They later found that the methanol had
accumulated in plasma and in the liver, and was bound to protein, thus determining that aspartame
contributes to the formation of formaldehyde adducts and its affects are cumulative Not only does
aspartame metabolize to form formaldehyde, but it even intensifies the toxicity of this chemical. Forty
percent of aspartame breaks down into excitotoxic amino acids, and formaldehyde’s toxicity increases
when it is in the presence of high levels of free radicals (Saito et al. 2005).
One of the dangerous consequences of methanol absorption is the increased risk of developing
lymphomas and leukemias. A case-control study in Argentina discovered that urinary tract tumors (UTT)
were directly correlated with aspartame consumption. The risk of UTT was significantly increased in
long-term aspartame users compared with non-aspartame users (Andreatta et al. 2008). Another longterm study which studied the affect of aspartame consumption on the incidence of tumors took place in
Italy. Soffritti and coworkers (2007) observed Sprague Dawley rats from eight weeks of age until natural
death. They observed a statistically significant increase in the incidence of malignant tumors among rats
that had ingested aspartame. These tumors included lymphomas, leukemia, preplastic, neoplastic, and
lesions of the renal pelvis and ureter. Since rodents have been found to be consistent predictors of
human cancer risks, they conclude that aspartame is a multipotential carcinogenic compound whose
carcinogenic effects are evident even at daily dose of 20 mg/kg bw.
Despite the compelling evidence, some researchers do not believe that methanol will cause
toxicity in humans when ingested in the form of aspartame. They assert that the alcohol is absorbed in
such minimal levels that it will be unlikely, and even impossible, to reach levels of toxicity associated
with cancers and lymphomas (Butchko et al. 2002). Nonetheless, there are still significant concerns with
aspartame’s production of formaldehyde.
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Conclusion
The results and conclusions of the different studies about the safety of aspartame are spread
over a large spectrum; views range from those who claim that aspartame is absolutely safe to those who
claim that it is toxic. Research is centered on the possible risks associated with the ingestion of each of
aspartame’s constituents. Regarding aspartate, many claim that high levels of this amino acid can induce
neuronal necrosis and endocrine disorders. A large group of scientists believe that the ingestion of
aspartame can lead to dangerous spikes in aspartate plasma levels when eaten in conjunction with MSG,
while many others believe that such a spike is impossible.
The debate about phenylalanine’s toxicity revolves around the ability of this amino acid to
interfere with LNAA at the blood-brain barrier. Some researchers are concerned that this constituent
can exacerbate mood disorders and induce seizures. However, the issue is still debated, and many
scientists have determined that aspartame’s phenylalanine will not cause adverse effects.
Methanol consumption has raised significant concerns since this alcohol is metabolized as
formaldehyde, a known toxin. Long-term studies have proven that the methanol component of
aspartame has caused lymphomas and leukemias in rats. Nonetheless, other scientists debate these
results and claim that typical ingestions of aspartame will not cause toxic effects.
Summary
Aspartame is one of the most controversial sweeteners. The pro-aspartame camp presents data
that shows that the ingestion of this sweetener does not lead to significant negative health effect. They
claim that the negative studies on lab animals are run with high concentration of materials that will
never be present during normal consumption. On the other hand, the anti-aspartame camp believes
that the fast digestion of aspartame leads to the concentration of its constituents in the body, causing
toxic effects. Clearly, more research must be conducted on the subject in order to conclusively
determine whether aspartame is harmful or not. In the interim, it would be advisable that people who
are susceptible to metabolic conditions which are possibly affected by aspartame should try to avoid
significant consumption of the sweetener.
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Folic Acid and Neural Tube Defects
Rachel Leah Feinstein
Neural tube defects (NTD) are the most common types of birth defects. Research shows that
folic acid taken periconceptionally greatly reduces the risk of having a NTD affected child. This paper will
explain the role that folate plays in the metabolism, specifically in synthesizing methionine. It will bring
evidence to show that methionine is crucial for normal neural tube development. In addition, it will
explore the genetic factor involved in folate metabolism and possible folate deficiency.
The central nervous system in an embryo begins as a flat region, which then rolls into a tube
known as the neural tube. The development of the neural tube is completed 28 days after the baby is
conceived. When the neural tube fails to close completely, it is known as a neural tube defect. The
nerves that are exposed to the environment due to the failure of the tube to close may become
damaged causing the affected baby to have a disability, specifically some measure of paralysis. Neural
tube defects are one of the most common birth defects, and affects 1.3- 2.0 babies in every 1,000 live
births in the United States. There are two main types of NTDs, depending on whether the cranial or
caudal end of the neural tube fails to fuse properly. The foremost cranial defect is known as
anaencephaly which is usually fatal. The main caudal defect is spina bifida (Pitkin, 2007).
The exact causes of NTDs are not clear. It is believed that a combination of environmental
factors, genetics, and nutrition contribute to the development of a NTD. However, as early as the 1970
scientists have suspected that folic acid taken by the pregnant mother helps prevent NTDs. In the United
Kingdom, R. W. Smithells noticed that a disproportionate amount of babies affected with NTD were born
to mothers of a lower socioeconomic class. He hypothesized that the birth defects may have been
caused by the mothers’ poor nutrition. He conducted tests and in 1976 reported that women who had a
child with an NTD had much lower red cell folate and vitamin C levels than mothers who had an
unaffected child (Smithells, Sheppard, & Schorah, 1976). He then conducted a placebo-controlled study
in which he gathered women who had already given birth to a NTD affected child. He gave one group of
women a multivitamin and an iron tablet containing 360 ug of folic acid. The group of women who were
given the vitamin pill only had a .5% occurrence of NTD births, while the control group had a 4% NTD
birth rate incidence (Smithells et al, 1981). Smithells results were published, however his experiment
was criticized because his subjects had not been randomized.
K. M. Laurence in Whales also performed experiments with folic acid based on Smithells’ works.
He performed a double blind randomized controlled trial of folate treatment prior to conception. Among
the group that received the folate, there were no NTDs in the group’s 44 births. However, in the control
group there was 6 NTDs in 67 births. Laurence’s work was not considered statistically significant since it
was performed on such a small population (Mills et al. 1996).
Smithells’ findings were eventually proved definitively by the Medical Research Council in 1991.
The MRC conducted a double-blind randomized study on women who had a previous NTD pregnancy.
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Women received 4 mg of folic acid, a multivitamin, both, or iron and calcium. There was a 74%
reduction of NTD births in the group taking folic acid, but no effect in the groups that did not receive
folic acid. Another study, conducted just one year later also helped to validate Smithell’s works. Czeizel
and Dudas in Hungary enrolled women who had never had an affected pregnancy. They were
randomized and given a multivitamin, some with .8 mg folic acid, and some without. The group of 2394
women who were given folic acid had no affected offspring, and the group of 2310 women who did not
receive folic acid had 6 babies with NTD (Mills et al. 1996).
Due to the solid evidence of the protective role of folic acid, public health officials recommend
women of childbearing age to take 400 ug of folic acid at least 4 weeks before conception, and through
the first trimester of pregnancy. Folic acid is the oxidized and most active form of folate. They may do
this by taking a folic acid supplement. They are also encouraged to eat folic acid enriched grain products
and large amounts of folate rich foods such as green leafy vegetables, or liver. The United States, as well
as other countries, have implemented a mandatory folic acid food fortification and have seen about a
50% reduction in the occurrence of NTDs (Lamers, Prinz-Langenohl, Bramswig, Pietrzik, 2006).
Despite the awareness of the role that folic acid plays in preventing NTDs, the exact mechanism
used to achieve this is not so clear and is still being studied. However, based on various experiments
scientists have come to a basic understanding as to how a folate deficiency would contribute to an NTD
development.
Folate is a term to describe a water- soluble B-complex vitamin and it serves many important
roles in the body. It is vital for cell division and homeostasis due to the essential role of folate
coenzymes in nucleic acid synthesis, methionine regeneration, and in the shuttling, oxidation and
reduction of one carbon units required for normal metabolism and regulation. There is an increase in
folate requirement in pregnant women to support the rapid growth of the embryo and uteroplacental
organs. There has been much focus on the role folate plays in methionine regeneration in regard to
studies of NTDs. In this process folate is reduced in the body to dihydrofolate and then to
tetrahydrofolate. Tetrahydrofolate acts as an acceptor molecule that accepts and donates one carbon
units in metabolic pathways. A one carbon unit is transferred from serine to THF by serine
hydroxymethyltransferase to form 5,10 methylene tetrahydrofolate. This compound is then reduced by
methylene tetrahydrofolate reductase (MTHFR) to form 5 methyl tetrahydrofolate. The 5 methyl
tetrahydrofolate is acted upon by methionine synthase together with a B-12 cofactor which facilitates
the removal of the N-5 methyl group from the 5 methyl tetrahydrofolate and deposits it onto
homocysteine. The homocysteine with the extra methyl group is known as methionine. A mother who is
lacking in folate would not be able to carry out this metabolic pathway, since 5 methyl tetrahydrofolate
is the only compound capable of this one carbon transfer (Bailey, & Gregory, 1999). It would therefore
seem plausible to say that mothers lacking in folate, and therefore at risk for an NTD baby, would have
elevated homocysteine levels and low methionine levels. Subsequent studies have indeed supported
this theory.
Steegers- Theunissen et al. (1995) was one of the first to report elevated amniotic fluid
homocysteine in women who were carrying an NTD fetus. Since then there have been many reports that
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plasma or amniotic fluid homocysteine is higher in NTD infants and their mothers than non-NTD infants
and their mothers. One such study was conducted by Mills in which blood samples were collected during
pregnancy from women carrying affected fetuses, and random women carrying healthy fetuses. The
homocysteine levels in the blood were measured, and the mothers if NTD fetuses had significantly
higher levels. These studies pointed to the relative inability of mothers with NTD babies to metabolize
homocysteine (Mills et al. 1996).
Since it has been established that NTD mothers have higher levels of homocysteine, research
turned to try to establish if too much homocysteine is what actually inhibits the neural tube closure. In
order to test this hypothesis Greene, Dunlevy and Copps (2003) cultured mouse embryos in the
presence of homocysteine thiolactone during the periods of cranial neural tube closure. While the
homocysteine thiolactone did cause growth retardation and other negative effects, it did not increase
the incidence of neural tube defects. Another study conducted by Afman, Blom, Van Der Put, and Van
Straaten (2003) and his colleagues administered homocysteine to chick embryos in ova. This resulted in
several malformations, but did not increase the number of NTDs. These results suggest that too much
homocysteine is unlikely to be the direct cause of NTD.
Since the overabundance of homocysteine in a mother of an NTD child does not seem to cause
the NTD, perhaps the lack of methionine that should have been made from the homocysteine plays a
role in the development of an NTD. Methionine is an essential amino acid that cannot be obtained
sufficiently through dietary intake and therefore must be synthesized by the body. Methionine formed
from homocysteine is converted to S- adenosylmethionine, which is a methyl donor for many reactions
including DNA methylation (Friso et al. 2002). This theory was tested in a few different ways. Coelho,
Weber, Klein, Daniels, and Thomas (1989) conducted a study in which he grew rat embryos in cow
serum. Cow serum has a much lower level of methionine than rat serum. They supplemented some cow
serum with methionine, and did not supplement others. There was a significant decrease in the
occurrence of NTD in the embryos that were grown in the serum that was supplemented with
methionine. Essein and Wannberg (1993) conducted a study involving pregnant mice with an Axd (axial
defect) mutation which is known to cause NTDs. They injected these pregnant mice with methionine on
days 8 and 9 of the pregnancy. At a dose of 180 mg/ kg body weight the methionine produced a 47%
reduction of NTDs. They also conducted studies with mice with the Axd mutation in which they
supplemented the mice with folinic acid, but it had no effect on the incidence of NTDs. This seems to
suggest that folate, or lack of it, is an indirect cause of NTD, and methionine is the needed product of
the folate for normal neural tube development. Perhaps the Axd mutation codes for a mutation in an
enzyme that is crucial to make methionine, or a vital product of methionine, but is not involved with
folate at all.
Shaw, Velie, Schaffer (1997) conducted a study concerning the effect of methionine on humans.
His study involved 424 mothers of NTD children, and 440 mothers of unaffected children. Each mother
was interviewed in which they answered a 100 item food frequency questionnaire. The data was then
established into quartiles of average daily maternal dietary intake of methionine in the 3 months before
conception. There was a 30- 40 % reduction in NTD affected pregnancies among women whose average
daily intake of methionine was above the lowest quartile. These observations were unrelated to the
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maternal level of folate intake, which supports the theory that methionine, or what methioine is
converted to, is what is actually crucial for normal neural tube development.
Assuming that methionine is vital for normal embryonic development, and the synthesis of
methionine is formed by homocysteine and 5 methyl tetrahydrofolate interaction, then it is clear how a
folate deficiency would result in a NTD. However, many studies since Smithells have reported that NTD
mothers are not necessarily folate deficient. One such study was conducted in Molloy and Kirke, Hillary,
Weir, and Scott (1985). They studied the serum samples taken during pregnancy from 32 mothers with
pregnancies affected by NTD and 395 randomly selected unaffected pregnant women. The serum folate
levels and vitamin B-12 levels (vitamin B-12 is the coenzyme that facilitates the removal of a methyl
group from the 5 methyl tetrahydrofolate onto the homocysteine) were measured and analyzed. To
analyze the data the information was sub- classified into folate deficient, possible deficient, and
sufficient ranges. The ranges were 0-2 ng/ml, 2.01- 2.7 ng/ml, and 2.71-20 ng/ml respectively.
Surprisingly, only 21.9% of the NTD group was deficient in either folate or vitamin B-12 while 22.8% of
the control group samples were. 43.8% of the NTD group, and 35.7% of the control group showed
sufficient serum concentrations of both folate and vitamin B-12. These results show that a significant
percent of women who had folate sufficient levels had a pregnancy affected by NTD. This seems to
indicate that folate deficiency may not be the sole or main cause of neural tube defects. There may be a
more subtle problem among women who gave birth to NTD babies than simply not consuming enough
folate as part of their diet. These results do not contradict Smithells’ findings, since he reported that
NTD mothers have lower red cell folate levels. This study was only able to measure the serum folate
levels, and this difference seems to be significant.
Red cell folate levels and serum folate levels were further investigated in other studies. Once
such study was conducted by Yates et al. (1986) measured vitamin levels in twenty women less than 35
years of age who had two or more NTD pregnancies. Each case was compared to a control female who
was matched for age, obstetric history, and social class. The red cell folate levels were measured and
showed a linear relationship with the number of NTD pregnancies. However, there was no significant
difference between the subjects and controls in relation to serum folate levels. The diets of the study
and control women were ascertained through a questionnaire. There was no statistically significant
difference between the folate dietary intakes of the two groups of women. However, regression analysis
showed a difference between the two groups in regard to the relationship of red cell folate to dietary
folate. This study provides additional evidence that low red cell folate is linked to NTD, but also
demonstrates that low red cell folate is not necessarily due to a folate deficient diet. The difference
between the red cell folate levels among women with similar folate intake supported the increasingly
popular idea that NTD may be linked to a disorder in folate metabolism, and not exclusively to a folate
deficient diet.
More recently, in 1992 Mills et al. conducted a study which measured the maternal serum folate
of 89 NTD pregnancies and 178 control pregnancies. This study also demonstrated no relationship
between maternal serum folate during pregnancy and the risk of NTDs (Mills et al. 1996).
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There is also a strong hereditary link for neural tube defects. The chance of having a NTD child is
about 0.15 percent. However, once a woman has a child with a NTD the chance of having a second child
with NTD is increased to about 2-5%. Furthermore, if the women herself has a NTD the chances of
having an affected baby increases. This supports the idea that there may be a genetic mutation that
predisposes someone for NTD among those who are affected by it (Genetics and Neural Tube Defects,
2005).
Due to the evidence provided by studies such as the ones mentioned above, there has been
much speculation that there is possibly a genetic defect that affects the metabolism of folate. To prove
this hypothesis researchers have identified several common polymorphisms of genes that code for
folate metabolizing enzymes, including the 677C / 677T and the 1298A/ 1298C alleles of 5, 10
methylenetetrahydrofolate reductase (MTHFR). These polymorphisms are common, and their frequency
varies by race and ethnicity. A recent study by Yang et al. (2008) tried to determine the role that these
different alleles play in the metabolism of folate and homocysteine levels.
Data for this study was taken from the third National Health and Nutrition Examination Survey
(NHANES III). The NHANES III endeavored to obtain a nationally representative sample of the civilian
United States population. Each survey participant was given an interview, a physical examination, and
gave a sample of their blood. The researchers genotyped selected polymorphisms of folate metabolizing
enzymes in DNA samples (obtained from the blood specimen) for 7159 individuals. They also measured
the serum folate levels and homocysteine levels in each blood sample. Based on the interviews of the
participants their average daily intake of folate was determined. The effects of MTHFR 677C/677T
genotype and the MTHFR 1298A/1298C genotype on the inverse relationship between folate intake and
serum homocysteine concentrations were then examined.
The researchers observed significant differences in the serum folate and homocysteine
concentrations for individuals with the MTHFR 677 TT genotype. The adjusted geometric mean of serum
folate concentration was 24.83 % lower if they had the TT genotype that if they had the CC genotype.
The adjusted geometric mean of serum total homocysteine concentration was 29.06% higher if they had
the TT genotype than if they had the CC genotype. The other polymorphism, 1298A/1298C, was not
significantly associated with serum folate or homocysteine concentrations.
Folic acid consumption also played an important part in determining serum folate levels. Those
with the 677 TT genotype that took 400 ug of folic acid per day had higher serum folate concentrations
than those with the MTHFR 677 CC who did not take folic acid supplements. As the folic acid
consumption increased, the difference between the levels of serum folate of the TT and CC genotypes
decreased significantly. The difference actually became non significant among the group who took
400ug or more of folic acid per day. However, homocysteine levels among the MTHFR 677TT only
decreased by 11-14% with the supplemental folic acid.
These results seem to indicate that having 677 TT alleles on the gene that codes for MTHFR
results in some sort of defect on the enzyme which causes lower folate levels than in someone who has
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the same folate dietary intake but has the 677 CC alleles. However, consuming a lot of folic acid,
specifically 400 ug per day, can overcome the problem and bring the serum folate to sufficient levels.
The exact explanation for what the polymorphism codes for, and how the folate is able to
overcome the defect can be explained. The 677T polymorphism occurs in exon 4 of the genetic code and
results in a valine substitution of alanine at codon 222. This valine lies on the binding site for the MTHFR
enzyme’s cofactor flavin adenine dinucleotide (FAD). This affects the binding of the FAD to the enzyme,
making the binding site exposed instead of imbedded in a barrel-like structure. The exposure results in a
weakened, thermolabile MTHFR/FAD complex and the MTHFR 677TT enzyme has been shown to
dissociate with the FAD cofactor more readily than the MTHFR 677CC enzyme. This results in decreased
enzymatic activity. The MTHFR enzymes with the 677TT genotype have a 30% in vitro MTHFR enzyme
activity as compared to the MTHFR 677CC enzymes. However, an abundance of 5methyltetrahydrofolate substrates have been shown to strengthen the complex and protect the MTHFR
from losing the FAD cofactor. This explains how consuming an abundance of folic acid overcomes a
natural genetic deficiency (Robien, & Ulrich, 2003).
The results of the study by Yang et al. explains the findings in the studies which show that
people of similar folate intake may have different red cell folate levels. However, in the those studies,
the women who had given birth to NTD children did have sufficient serum folate levels, while in the
study by Yang the MTHFR reduced activity was specifically reflected in low serum levels. It is possible
that this can be explained simply by the different states of the subjects of the studies. The studies that
showed similar serum levels were conducted on pregnant women. It has already been established that
pregnant women are in high need of folate. The plasma is the provider of folate during pregnancy and
therefore the body does al it can to ensure sufficient serum folate. When the maternal serum folate
reaches deficient levels, folate is taken from the red cells that serve as folate storage tissue (Lamers,
Prinz-Langenhol, Bramswig, & Pietrzik, 2006). That would explain the consistent findings of low red cell
folate levels, but sufficient serum folate levels of the NTD mothers. However, the study of
polymorphisms was conducted on a representational population of United States residents, and
therefore presumably only has a small percent of pregnant women. Since folate is not as desperately
needed among non-pregnant people, the body has no urgent need to bring up the serum folate levels,
and therefore they remain deficient.
If the 677TT MTHFR polymorphism is actually what leads to low serum folate and high total
homocysteine levels, perhaps it would be more efficient to simply supplement the body with what the
MTHFR should be synthesizing rather than with folic acid which stabilizes the enzyme. This speculation
was proven true in a study by Lamers et al. (2006). The study involved 144 women aged 19-33 who were
not pregnant or lactating. The study was a 24 week double-blind placebo-controlled trial. The women
received either 400ug of folic acid, 416 ug [6S] 5 methyltetrahydrofolate, 208 ug [6S] 5
methyltetrahydrofolate, or a placebo daily. Blood samples were collected every 4 weeks of the study. At
baseline, the 4 groups did not differ significantly with respect to red cell and serum folate concentration.
No change in dietary intake was observed throughout the study period. Although all 3 groups receiving
supplements showed significant red cell and serum folate increases, the increase in red cell folate and
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serum folate was significantly greater in the group receiving 416 ug [6S] 5 methyltetrahydrofolate than
the other 2 groups. The group that received 400 ug of folic acid had the second highest increse.
This study proves that supplemental [6S] 5 methyltetrahydrofolate at approximately the same
dosage as supplemental folic acid is more efficient than folic acid at raising folate levels. This supports
the idea that the lag in the folate metabolism present in some people occurs at the MTHFR enzyme
which is supposed to synthesize 5 methyltetrahydrofolate. Therefore providing the body with the
product of the enzyme overcomes the defect more efficiently than trying to stabilize the enzyme with
additional folic acid.
The role that folic acid plays in the prevention of the occurrence of a NTD is well documented
and proven. Folic acid aids in the deposition of a methyl group on homocysteine, thereby creating
methionine. Methionine is then converted to other substances, such as S- adenosylmethionine, which is
essential for normal embryonic development. Pregnant women who are folate deficient may therefore
not have sufficient methionine levels to support a growing embryo. This could lead to birth defects, such
as the failure of the neural tube to close properly. Pregnant women may be folate deficient due to a
poor diet. However, even women who do have a folate sufficient diet may have low red cell folate
serum levels if they have the 677TT MTHFR polymorphism. This genetic defect can be overcome by
consuming an abundance of folic acid, beyond what is normally considered sufficient. Today there is
much effort expended on educating the public about the beneficial role of folic acid, and encouraging
women of child bearing age to take folic acid supplements.
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Cholera: An Overview of a Disease
Ezriel Leifer
Abstract
Although the disease, cholera, has been recognized since antiquity, the bacteria responsible for causing it
was only discovered in the mid-19th century. Since 1817, cholera has spread on a global basis to cause
seven pandemics. According to information reported to the World Health Organization in 1999, almost
8,500 people died and another 223,000 became sick with cholera worldwide. During the period between
full outbreaks, the cholera organism, Vibrio cholerae, thrives in brackish waters, in harmless as well as
disease-causing forms. Vibrio cholerae is just one of a variety of ocean-borne microbes that can sicken
humans via seafood, drinking water, and swimming. Location, time, and intensity of cholera epidemics
can now be accurately predicted from satellite observations of sea surface temperature, sea surface height,
and chlorophyll in the water. Bacteria such as Vibrio cholerae have been found to be able to communicate
with members of their own species and others to coordinate their behavior in response to cell density in a
process known as quorum sensing, which relies on the production of and sensitivity to one or more
secreted signal molecules. A growing body of scientific studies has identified a complex quorum sensing
network in the human pathogen Vibrio cholerae. To gain a better understanding of this pathogen, this
study provides an overview of the bacterium Vibrio cholerae, the mechanism of its virulence, a discussion
concerning the symptomatology of the bacterium and its epidemiology. An analysis of how quorum
sensing influences the virulence of the bacterium is followed by a discussion of diagnostic and treatment
considerations. A discussion of ongoing preventative measures is followed by a summary of the research
and salient findings in the conclusion.
Introduction
As the current swine flu epidemic reaches pandemic proportions, attention has been drawn away
from yet another continuing threat to global health in the form of Vibrio cholerae and the cholera disease
it can cause. Despite this inattention, the threat of cholera remains, and researchers are actively involved
in investigating its etiology to identify the best practices in its prevention and treatment. To gain a
snapshot of the historic and current efforts to combat this disease, this study provides an overview of the
bacterium, Vibrio cholerae, the mechanism of its virulence, a discussion concerning the symptomatology
of the bacterium and its epidemiology. An analysis of how quorum sensing influences the virulence of the
bacterium is followed by a discussion of diagnostic and treatment considerations. A discussion of ongoing
preventative measures is followed by a summary of the research and salient findings in the conclusion.
Review and Analysis
Overview of the Bacterium, Vibrio Cholerae
The cholera disease that is caused by Vibrio cholerae has been a source of dread for mankind
since the first recorded pandemic in 1817 because of the high death rate associated with it and the rapidity
with which it spreads. To date, about 200 O antigens have been distinguished serologically; however, just
O1 and O139 have been found in epidemic and pandemic cholera isolates (Salim, Lan & Reeves, 2005).
One of the preeminent researchers into the spread of cholera, Colwell, reports that, “Cholera, a diarrheal
disease, has been with us for a very long time, even being mentioned in ancient Sanskrit writings. A
medical textbook published in 1875 reported cholera to be a global pandemic, consistently appearing in
Ezriel Leifer, BS ’09 was a Biology major at Touro College. He is currently attending LIU School of Pharmacy.
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India, Bangladesh, Latin America, and Africa. Today, cholera remains a serious problem” (2006, p. 753).
The bacterium that causes cholera was first identified in 1854 and has continued to be investigated since
that time (Faruque & Nair, 2008).
This scientific interest has been fueled in large part by the fact that the disease has become
prevalent worldwide rather than being restricted to the Indian subcontinent as in years past. In this regard,
Colwell (2006) reports that, “Until the nineteenth century, cholera was generally confined to the Indian
subcontinent, but it then began to appear in Europe and the Americas as well. Since 1817, Western
medical history describes seven global pandemics of cholera that have spread illness and death around the
world. “The second of these seven pandemics reached the United States in 1832, traveling from New
York to Philadelphia in a couple of weeks, and then cases appeared along the Atlantic coast all the way to
the Gulf of Mexico” (Colwell, 2006). Likewise, according to Osborne (2008), “The pandemic that swept
North American cities in 1832 was caused by a comma-shaped bacterium, Vibro cholerae, known by
various names including Asiatic cholera and Cholera morbus. It is now generally accepted that Vibro
cholerae originated in India, where cholera was endemic, and first reached the West in the early
nineteenth century”.
In their account of historic efforts to combat the spread of cholera, Albertine, Persily and
Riegilman (2007) repeat a well-known story thusly: “In 1855, pioneering epidemiologist John Snow
traced the emergence of cholera in London to the public water supply. He persuaded authorities to remove
the pump handle on the Broad Street well and thereby slowed and then stopped an outbreak of cholera”. It
should be noted that Colwell (2006), though, suggests that the outbreak was stopped as a result of the
operation of natural forces more than this
straightforward public health tactic, but the fact remains that the bacterium has been with mankind for
millennia and efforts to stop its spread remain an ongoing source of investigation throughout the world.
The seventh pandemic (1961-present) is still widespread and has a severe impact on three
different continents. The sixth pandemic ended in 1923, but the clone persisted at least until the 1990’s
(Safa, Bhuiyan, Alam, Sack & Nair, 2005). In addition, a number of cholera outbreaks were reported after
the sixth pandemic retreated, but before the start of the seventh pandemic. Isolates from these outbreaks
were recognized as different from those of the sixth pandemic and were allocated to the El Tor biotype,
while the sixth and fifth pandemics, both of which had been studied microbiologically, were referred to as
the classical biotype (Safa et al.).
The outbreaks of the El Tor biotype took place in Indonesia and the Middle East (1926-1960) and
are frequently described as being prepandemic isolates because they were later viewed as predecessors of
the subsequent seventh pandemic, an episode that is also of the E1 Tor biotype (Safa et al.). Today, the
environmental aspects of V. cholerae have been the focus of a considerable amount of research, and the
major components of the El Tor phenotype have been shown to be present in most environmental isolates;
the classical biotype is thought to have emerged through the loss of characters that are otherwise
widespread in the species (Safa et al.). In addition, instances of sporadic indigenous cholera have been
detected in Australia as well as the United States, both of which have been of the O1 El Tor biotype (Safa
et al.). These are generally referred to as the US Gulf and Australian clones. All of the pathogenic forms
discussed above had the O1 serotype, but in 1992 a variant of the seventh pandemic appeared with a new
O antigen, O139; this variant is known as V. cholerae O139 Bengal (Safa et al.).
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Mechanism of Virulence for Vibrio Cholerae.
Adherence to intestinal cells. The infectivity of V. cholerae is related to its ability to defeat the
protective qualities that are typically present in the intestinal cells (Sparling, 1985). Microbial adherence
to epithelial cell surfaces has been implicated as the first step in the initiation of several infectious
diseases. Subinhibitory concentrations of antibiotics affect the adherence properties of microorganisms in
various ways. They can inhibit the expression of fimbriae and the synthesis of other surface components,
and they may also cause the release of constituents from the cell. The ability of antibiotics to affect the
properties of microbial adherence to cell surfaces may be an important criterion in selecting an antibiotic
for therapy. The relationships of V. cholerae have been studied in several ways, but the most useful
insights have come from multilocus enzyme electrophoresis and more recently by multilocus sequence
analyses (Salim et al.). According to Paz and Broza, “Vibrio cholerae bacteria are common hitchhikers
attached to the surface of adult nonbiting midges (observed mainly with Chironomus sp., family
Chironomidae). Both males and females have been reported to carry Vibrio cholerae strains that remain
viable and culturable even after 14 days”. In fact, researchers have been investigating the ability of Vibrio
cholerae to adhere to animal cells and different ligands involved in intestinal colonization for some time,
including virulence-associated toxin co-regulated pilus (TCP), outer membrane proteins, and
lipopolysaccharides (Zampini et al. 2006). According to these researchers, “Its interactions with
substrates present in the aquatic environment have been described more recently. V. cholerae O1 El Tor
does not use TCP to form a biofilm on abiotic surfaces (borosilicate and cellulose), but rather the
mannose-sensitive hemagglutinin (MSHA) pilus, which has no role in pathogenicity” (p. 267). The ability
of V. cholerae to attach to chitin
has been demonstrated to be independent of the MSHA pilus, a finding that indicates divergent pathways
for biofilm formation on nutritive and nonnutritive abiotic surfaces (Zampini et al.). Researchers have
also determined that MSHA is involved in V. cholerae O1 El Tor and O139 adhesion to the exoskeleton
of the planktonic crustacean Daphnia pulex and other ligands are believed to be used by V. cholerae O1
classical strains for zooplankton adhesion (Zampini et al.). In addition, V. cholerae O1 classical strain
membrane proteins have been found to mediate N-acetyl glucosamine (GlcNAc)-sensitive attachment to
chitin particles in vitro (Zampini et al.).
Release of toxins and their operation. The fatal effects of the disease are mainly due to the
cholera toxin produced by specific strains of Vibrio cholerae (Paz & Broza). According to DNA
researcher Lang, “Instead of having one circular chromosome, like most bacteria, the organism has two.
The larger chromosome, comprising nearly three million base pairs, contains most of the organism's
critical genes, including those coding for the disease-causing toxins and proteins that carry out essential
cell functions” (2000, p. 39). The ability of V. cholerae to adhere to epithelial cell surfaces and release
these disease-causing toxins has been cited as the first step in its infectivity (Shibl, 1985). In this regard,
Todar (2009) reports that, “Cholera toxin activates the adenylate cyclase enzyme in cells of the intestinal
mucosa leading to increased levels of intracellular cAMP, and the secretion of H2O, Na+, K+, Cl-, and
HCO3 into the lumen of the small intestine. The effect is dependent on a specific receptor, monosialosyl
ganglioside (GM1 ganglioside), present on the surface of intestinal mucosal cells” (p. 3). The specific
manner in which V. cholerae operates is described by this clinician thusly: “The bacterium produces an
invasin, neuraminidase, during the colonization stage which has the interesting property of degrading
gangliosides to the monosialosyl form, which is the specific receptor for the toxin” (Todar, p. 3). The
toxin released by V. cholerae contains (a) 5 binding (B) subunits of 11,500
daltons, (b) an active (A1) subunit of 23,500 daltons, and (c) a bridging piece (A2) of 5,500 daltons; the
latter links A1 to the 5 binding subunits (Todar). After V. cholerae has penetrated the cell, the active
subunit transfers ADP ribose from NAD+ to a protein (called Gs or Ns) enzymatically; this process
controls the adenylate cyclase system situated on the interior of the plasma membrane of mammalian cells
(Todar). According to Todar, “Enzymatically, fragment A1 catalyzes the transfer of the ADP-ribosyl
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moiety of NAD+ to a component of the adenylate cyclase system. The process is complex. Adenylate
cyclase (AC) is activated normally by a regulatory protein (GS) and GTP; however activation is normally
brief because another regulatory protein (Gi), hydrolyzes GTP”.
Typically, the active subunit fragment changes the attachment of ADP-Ribose (ADPR) to the
regulatory protein thereby creating Gs-ADPR, a protein from which GTP is unable to be hydrolyzed.
Because GTP hydrolysis serves to shut down the adenylate cyclase process, the enzyme continues to be
active in the cell (Todar). As a result, the bottom-line impact of the toxins released by V. cholerae are to
cause cAMP to be produced at an inordinately high rate, a process than in turn stimulates mucosal cells to
discharge large amounts of Cl- into the contents of the intestine (Todar). Thereafter, H2O, Na+ and other
electrolytes are produced as a result of the osmotic and electrical gradients that are the result of the loss of
Cl- (Todar). In sum, then, “The lost H2O and electrolytes in mucosal cells are replaced from the blood.
Thus, the toxin-damaged cells become pumps for water and electrolytes causing the diarrhea, loss of
electrolytes, and dehydration that are characteristic of cholera” (Todar, p. 3). Neither Vibrio cholerae,
though, nor the toxins it releases are capable of passing through the gut wall (Gibbs, 2005).

Symptomology of Vibrio Cholerae.
Accounts of the symptoms associated with the 1832 North American pandemic were grisly in
their descriptions. For instance, Osborne reports that “Victims of the disease were stricken with severe
diarrhea and vomiting, accompanied by excruciatingly painful cramps through the trunk and legs. As
dehydration continued, the bodily fluids were excreted as ‘rice water’ and the victim quickly collapsed
and turned blue. “Often, fifty per cent or more of those who caught cholera died, with death coming to the
more fortunate victims in as little as four to six hours “(p. 30). Empirical accounts from the 1832 North
American pandemic described one victim as being: “. . . a young woman of apparently twenty-five ...
absolutely convulsed with agony. Her eyes were started from their sockets, her mouth foamed, and her
face was a frightful livid purple. She had been taken in perfect health only three hours before, but her
features looked to me marked with a year of pain. The first attempt to lift her produced violent vomiting,
and I thought she must die instantly” (A walk through a cholera hospital, 1832, p. 37).
Epidemiology of Vibrio Cholerae.
One of the first aspects that researchers learned about cholera was about how the disease was
transmitted: “The disease was transmitted through human feces, generally ingested in drinking water. It
first escaped the Indian subcontinent in 1817, reaching Moscow in September 1830 and thence westward
across Europe. “The mysterious origins and terrifying nature of the disease added to the sense of dread it
created in Europe and North America” (Osborne, p. 30). In 2000, scientists identified the entire order of
paired chemical building blocks that constitute the DNA of the deadly cholera bacterium, Vibrio cholerae,
and found that it is “a comma-shaped microbe [that] causes a severe diarrheal disease that has been
endemic in southern Asia for at least 1,000 years” (Lang, 2000). Cholera continues to represent an
important cause of morbidity and
mortality in many regions of the world, and there is currently a high incidence of fresh outbreaks in
Africa (Paz & Broza, 2007).
The transmission of cholera epidemics may also be related to the dominant wind direction over
land (Paz & Broca, 2007). These researchers examined the geographic diffusion of three cholera
outbreaks through their linkage with the wind direction: a) the progress of Vibrio cholerae O1 biotype El
Tor in Africa during 1970-1971 and b) again in 2005-2006; and c) the rapid spread of Vibrio cholerae
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O139 over India during 1992-1993. In addition, it is possible that the influence of the wind direction on
windborne dissemination by flying insects, which may serve as vectors, plays a role. The analysis of air
pressure data at sea level and at several altitudes over Africa, India, and Bangladesh by Paz and Broca
found a correspondence between the dominant wind direction and the intracontinental spread of cholera.
According to Holzman (2007), Vibrio cholerae is just one of a variety of ocean-borne microbes which can
sicken humans via seafood, drinking water, and swimming. Location, time, and intensity of cholera
epidemics can now be accurately predicted from satellite observations of sea surface temperature, sea
surface height, and chlorophyll in the water (Foster, 2000). Likewise, Colwell (2006) notes that, “In 1977,
my coworkers and I reported that Vibrio cholerae, the causative agent of cholera, could be cultured from
Chesapeake Bay water samples. It was the first report of the isolation of the V. cholerae from noncholeraendemic geographical areas; cholera had not been reported in Maryland since the 1900s. “It was difficult
for us to make our case, namely that the cholera vibrio was a native inhabitant of the Chesapeake Bay,
since cholera had not occurred in the region.
Despite this lack of evidence, though, these researchers did in fact identify Vibrio cholerae in the
Chesapeake Bay and thereafter applied molecular techniques to demonstrate that
the bacterium is naturally occurring in the aquatic environment, with annual peaks in the spring and fall.
In addition, Colwell and her colleagues found that the V. cholerae is associated with plankton. We now
know that river, estuary, and coastal waters are reservoirs of these bacteria globally, but their data
showing an environmental source of the cholera bacteria implied a paradigm shift for the medical
community. “It has taken about 20 years for the paradigm change of cholera being transmitted only by
person-to-person contact to the recognition that the cholera vibrio exists in the environment as a natural
inhabitant (p. 753). In addition, Colwell and her associates determined that the bacterium experiences a
dormant phase between outbreaks and epidemics and through the use of gene probe molecular techniques
were able to prove its year-round presence in the environment.
As noted above, V. cholerae O1 classical strains adhere to zooplankton, and Colwell and her
colleagues determined that this relationship with zooplankton was particularly important. According to
these researchers, “In the spring, when the water warms, phytoplankton become abundant; using sunlight
for energy, the population of phytoplankton increases significantly. That population increase is followed
by blooms of zooplankton, the miniature ‘cattle’ of the sea, which graze on the phytoplankton. We were
able to show a relationship of sea surface temperature increase with onset of cholera epidemics because of
the fact that vibrios comprise the natural microbial flora of zooplankton, the populations of which
increase spring and fall in annual cycles. The seasonal pattern of cholera follows the seasonal rise and fall
in sea surface temperature and height (Colwell,).
In 1991-1992, a massive cholera epidemic took place in Peru and about 200,000 cases and 5,000
deaths were reported as a result of this epidemic; this was an unprecedented occurrence because cholera
had not been reported in South America for almost a century
(Colwell). Moreover, the epidemic took place during a period of a strong El Nino climatic event. Based
on climatologists’ prediction concerning another comparable El Nino event in 1997-1998, Colwell and
her associates hypothesized that there was a linkage of the 1991-1992 cholera epidemic with El Nino and
predicted additional cholera outbreaks would occur in 1997-1998. As Colwell notes, “With colleagues
from Peru, Chile, Ecuador, Brazil, and Mexico, we conducted a training session on molecular techniques
for direct detection of the V. cholerae in water and plankton. As the sea surface temperatures in these
Latin American countries increased in 1997 because of E1 Nino, the team was able to detect the presence
of the cholera bacteria associated with plankton, with numbers of the bacteria increasing from spring to
summer (September 1977 to March 1998) and cases of cholera occurring in late November through the
summer of 1998” (p. 753).
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Colwell and her colleagues were able to conclude that E1 Nino is another important climate
factor related to cholera, notably in cholera-endemic countries. The cases of cholera in Peru in 1997-1998
were directly correlated with sea surface temperature. The relationship of the disease with this climate
factor was statistically significant. In Bangladesh and other countries where severe cholera epidemics
occur, such as Peru, Indonesia, and India, the influence of monsoons or severe weather is important.
Matlab, near Dhaka, Bangladesh, comprises a "hotspot" of cholera. The villages are constructed around
bodies of water, and specific locations of epidemics have been determined. Research on cholera has been
conducted in Matlab by Colwell et al. since 1975. The influence of the Himalayas on the weather in
Bangladesh is significant, because the monsoon rains wash nutrients into the rivers and ponds. Typically,
houses in Bangladesh are located at the edge of a pond, from which villagers draw their water for
household use. A definable relationship between sea surface temperatures, sea surface height, and cholera
epidemics was established and published in the proceedings of the National Academy of Science (Lobitz
et al., 2000). Taken together, the complex factors of sea surface temperature, sea surface height, and
zooplankton populations provide a predictive capacity for cholera epidemics in developing countries that
derives from climate monitoring through satellite sensors (Colwell, 2006).
Finally, with the assistance of sociology researchers working in Bangladesh, they were able to
test the hypothesis they constructed: that if they could remove zooplankton from the water the villagers
used to meet household needs, the incidence of cholera could be reduced. With a very simple filtration
technique that Colwell et al. devised using sari cloth folded in 4 layers, the researchers were able to
reduce cholera by approximately 50 percent in villages where families had been instructed in the filtration
method. The complex of plankton, people, and climate, together with a simple solution based on science
(under the electron microscope, the folded sari cloth could be seen to provide a 20 micron filter--and the
zooplankton range in size roughly 50 to 200 microns), provides the interrelationship that allows an
understanding of a global infectious disease--an understanding that would not otherwise be possible.
Moreover, studies conducted by the Smithsonian Environmental Research Center in recent years
have also determined that cholera is far more prevalent in ballast water than previously thought; a
sampling of ballast water from fifteen vessels entering Chesapeake Bay identified one strain of cholera,
Vibrio cholerae O1, on every ship surveyed. In additional, a different strain of cholera, Vibrio cholerae
O139, which had been previously unidentified in the United States, was identified in the ballast water of
fourteen of the fifteen vessels surveyed (Foster, 2000).

How Quorum Sensing Influences the Virulence of the Bacteria Vibrio Cholerae.
According to Cámara, Hardman, Williams and Milton (2002), “Bacteria can communicate with
members of their own species and others to coordinate their behavior in response to cell density. This
phenomenon, known as quorum sensing, relies on the production and sensing of one or more secreted
signal molecules. A recent study identifies a complex quorum sensing network in the human pathogen
Vibrio cholerae (p. 217). In this regard, Tsou, Cai, Liu, Zhu and Kulkarni (2009) report that, “The
quorum-sensing pathway in Vibrio cholerae controls the expression of the master regulator HapR, which
in turn regulates several important processes such as virulence factor production and biofilm formation.
While HapR is known to control several important phenotypes, there are only a few target genes known to
be transcriptionally regulated by HapR (p. 2747). In this study, Tsou and her colleagues combined
bioinformatic analysis with experimental validation to discover a set of novel direct targets of HapR. The
findings of the Tsou et al. study provide evidence for two distinct binding motifs for HapR-regulated
genes in V. cholerae as follows. The first binding motif is similar to the motifs recently discovered for
orthologs of HapR in V. harveyi and V. vulnificus; these results also demonstrate that this binding motif
can vary in length in V. cholerae; the second binding motif shares common elements with the first motif,
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but in contrast to the first binding motif, the second is fixed in length and does not have dyad symmetry at
the terminal points (Tsou et al.).

Figure 1. Quorom sensing in Vibrio harveyi.
Source: Camara et al.
In V. harveyi, a harmless marine bacterium closely related to V. cholerae, quorum sensing serves
to activate bioluminescence (luxCDABE) at high cell density levels; to accomplish this, two parallel
signaling systems are used to control light production. Likewise, as shown in Figure 2 below, quorum
sensing in V. cholerae functions by restricting virulence gene expression at high cell density through the
use of three parallel signaling systems as follows:
1. System 1 includes CqsA, a putative synthase for the unidentified CAI-1 signal molecule, and
CqsS, a hybrid sensor/kinase that responds to the CAI-1 signal.
2. System 2, LuxSPQ, is identical to that of V. harveyi (see above).
3. System 3 has not been characterized; however, this system is believed to respond to an
intracellular signal and is therefore thought to be unrepresentative of a true quorum sensing
system. System 3 does not seem to transmit its signal through LuxU but rather
directly through LuxO, the pivotal regulator for all three systems. Like the V. harveyi system, LuxO
is activated via phosphorylation at low cell density and, together with σ54, activates the expression of
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an unidentified repressor that blocks the production of HapR, which acts as a repressor of virulence
gene expression. As a result, at low cell density, virulence genes are expressed; at high cell density,
though, LuxO remains inactive and cannot repress HapR. As HapR is now expressed, virulence gene
expression is repressed (Camara et al.).

Figure 2. Quorum sensing in Vibrio cholerae.
Source: Camara et al.
The quorum sensing responses in V. harveyi and V. cholerae represent instances of complex cell–
to-cell communication techniques that focus multiple cell-density–dependent, and perhaps independent,
signals via an alternate regulatory pathway to regulate bacterial behavior (Camara et al.). According to
these researchers, “Variations on the complexity or organization of these multiple-channel signaling
systems may be forthcoming, as components of the V. harveyi-like signaling systems have been found in
V. fischeri as well as the fish pathogen Vibrio anguillarum11–13; however, adding yet more complexity
to the process, both of these organisms also possess LuxI/LuxR-type quorum sensing signaling systems”
(Camara et al., p. 218). The coordination of a multi-cellular response to rapidly adapt to changes that take
place in the surrounding environment is a useful survival strategy for pathogenic and non-pathogenic
bacteria alike (Camara et al.). Just as other forms of life respond to the density levels of their populations
in different ways, so too does the V. cholerae. In this regard, Camara and his associates report that, “Cell
density is just one of a multitude of signaling parameters that a bacterium faces in any given environment,
and coordination of all signals into a physiological response will require intersystem cross-talk.
Incorporation of quorum sensing into a global network of regulatory responses may be required to
increase selectivity and efficiency of a bacterium’s response to the stresses it encounters in its growth
environment” (Camara et al., p. 218).
One unexpected outcome of a study by Miller et al. (2002) was that, in contrast to many other
bacterial pathogens, quorum sensing in V. cholerae serves to repress, rather than activate, virulence gene
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expression at high cell density levels in vitro (Camara et al.). A speculative model was advanced that
indicated that following initial colonization (low cell density), LuxO represses HapR, which is also a
repressor of virulence gene expression, thereby permitting colonization of the intestines and cholera toxin
production. In this regard, Camara et al. add that, “As the bacterium multiplies, the quorum sensing signal
molecules accumulate and activate the two quorum sensing systems, which inactivate LuxO. HapR is then
produced, repressing virulence gene expression while activating the production of the protease, HapA”.
(Camara et al., p. 218).
HapA is believed by scientists to promote the detachment of the bacteria from intestinal tissue, thus
facilitating the spread of the pathogen. As there is still a third unidentified signaling system influencing
gene regulation through the LuxO regulatory cascade, and additional regulators of virulence gene
expression to be considered, the actual role of signaling systems 1 and 2 in the virulence of V. cholerae in
vivo remains unclear. According to these researchers, “Nonetheless, the model proposed for V. cholerae
should provide an exciting twist on the role of quorum sensing in virulence” (Camara et al., p. 218).
Finally, a study by Zhu, Miller, Vance, Dziejman, Bassler and Mekalanos (2002) notes that the
production of virulence factors including cholera toxin and the toxin-coregulated pilus in the human
pathogen Vibrio cholerae is strongly influenced by environmental conditions. These researchers report
that, “The well-characterized ToxR signal transduction cascade is responsible for sensing and integrating
the environmental information and controlling the virulence regulon” (p. 3129). In their timely study,
“Quorum-sensing regulators control virulence gene expression in Vibrio cholerae,” Zhu et al. demonstrate
that besides the known components of the ToxR signaling circuit, quorum-sensing regulators are involved
in regulation of V. cholerae virulence. These researchers concentrated on the regulators LuxO and HapR
because homologues of these two proteins control quorum sensing in the closely related luminous marine
bacterium Vibrio harveyi in this study. According to Zhu and his associates, “Using an infant mouse
model, we found that a LuxO mutant is severely defective in colonization of the small intestine. Gene
arrays were used to profile transcription in the V. cholerae wild type and the LuxO mutant. These studies
revealed that the ToxR regulon is repressed in the LuxO mutant, and that this effect is mediated by
another negative regulator, HapR. We show that LuxO represses HapR expression early in log-phase
growth, and constitutive expression of HapR blocks ToxR-regulon expression.
Additionally, LuxO and HapR regulate a variety of other cellular processes including motility, protease
production, and biofilm formation. Together these data suggest a role for quorum sensing in modulating
expression of blocks of virulence genes in a reciprocal fashion in vivo” (p. 3130).
Diagnostic and Treatment Considerations.
In many ways, Vibrio cholerae is an elusive bacterium that can elude ready detection that
confounds diagnosis. In this regard, Henrickson, Wong, Allen, Ford and Epstein (2001) report that some
gram-negative organisms such as V. cholerae are capable of adapting to low-nutrient environments
through reductive division; in other words, although there is no change in total biomass, more organisms
develop but they develop at a significantly reduced metabolic rate. When there are unfavorable
environmental conditions, such as cold or reduced nutrients, Vibrio cholerae bacteria can shrink to 1/300th
of its original size and enter a dormant state; remaining in the dormant state for extended periods of time,
increasing in size when environmental conditions once again become favorable. Moreover, V. cholerae
can become nonculturable on routine culture plates, but remain viable, and could regrow under
appropriate conditions (Henrickson et al.).
As noted above, cholera has a rapid onset and most frequently occurs in epidemics that are spread
through contaminated water. According to Long, “Oral rehydration is an effective treatment, but left
untreated, cholera causes severe diarrhea that has a high mortality rate, particularly in young children” (p.
39). Even some simple precautionary methods can reduce the incidence of infection by Vibrio cholera,
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though. For instance, Holzman (2007) emphasizes that if people in the least stable situations--for
example, in war-torn developing countries—are provided with sufficient warning, they could filter
drinking water using low-tech devices, cutting
the infection rate by 50%. Researchers have successfully monitored and predicted cholera epidemics in
Bangladesh through the use of satellites, as reported in the 15 February 2000 issue of Proceedings of the
National Academy of Sciences (Holzman). In this regard, Dremeaux (2003) reports that, “Ingesting a high
dose of the waterborne bacteria Vibrio cholerae O1 produces cholera, an infection that causes severe
dehydration brought on by acute diarrhea and vomiting. Left untreated, cholera can kill a person in 24
hours. Filtering water with a folded piece of old cloth before drinking it cuts the rate of cholera
contraction by half, according to a three-year study in 65 Bangladeshi villages published in January 2003
in the U.S. journal Proceedings of the National Academy of Sciences” (p. 9). According to Gibbs (2005),
“Up to 90 per cent of cases of cholera will have only mild diarrhea. The remainder may exhibit severe
watery diarrhea leading to dehydration. Since neither the bacteria nor its toxins can pass through the gut
wall and into the blood, cholera does not increase the sufferer's temperature. In severe cases, a simple
antibiotic such as Tetracycline will decrease the diarrhea. Rehydration is imperative. “Oral rehydration
salts are usually sufficient, but severe cases will need intravenous fluids” (p. 101).
Discussion.
As noted above, simply filtering contaminated water with a folded piece of old cloth before
drinking it reduces the rate of cholera contraction by fully 50 percent. According to Dremeaux (2003),
“The finding has the potential to save thousands of lives annually. Fabric from saris, the flowing, colorful
garments South Asian women often wear, was cheap and readily available to the 133,000 people who
participated in the study, and comparable fabrics could function as filters for populations at risk for
cholera around the world” (p. 9). The sari cloth does not trap V. cholerae per se, but rather the copepods,
a type of zooplankton onto whose mouths, surfaces, and egg cases the vibrios attach (Dremeaux). While a
majority of the vibrios did remain
free in the filtered water, their numbers were frequently diminished sufficiently to fall short of an
infective dose, estimated at [104] to [106] V. cholerae; in fact, the dilution lowered the rate of cholera
infection by almost half (48%). According to Dremeaux, “For those who did contract cholera via filtered
water, the severity of the disease appears to have lessened, the report says. Electron microscopy had
revealed that sari cloth, when folded four to eight times, would create a filter of approximately 20 mm
pore size, removing all copepods--and the cholera-causing bacteria attached to them--from the water. The
old saris used in the experiment were expected to be more effective than new ones, their laundered fabric
resulting in a smaller pore size” (p. 9). Although clean potable water would be preferable of course, and
boiled water would be an acceptable alternative, there remains a paucity of fuel for many villagers to use
for this purpose. In this regard, Dremeaux reports, “Rivers and ponds are a common source of drinking
water for the villages in rural Matlab, Bangladesh. Boiling water, which kills all waterborne
microorganisms, is often impossible for the villagers, who are hard-pressed to find dry wood for fuel or
the money to buy it. High concentrations of arsenic in the groundwater make well sources a poor
alternative (Dremeaux, p. 9). Although nylon mesh filter was nearly as effective as the sari cloth in
reducing cholera, that material is more costly and harder to find in rural Bangladesh than material from
saris (Dremeaux). In sum, Colwell (2006) emphasizes that, “The interaction of humans, cholera bacteria,
the zooplankton host of the bacterium (the copepod), and the environment in the case of cholera can be
employed to make reasonable predictions about this climate-driven disease. The issues are truly
international and represent those that comprise a global scientific enterprise and encompass many other
infectious diseases” (p. 754).
Conclusion
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The research showed that the disease caused by Vibrio cholerae has plagued mankind for
thousands of years, but the pathogen that was responsible for causing cholera was only discovered a
century and a half ago. Over the past two centuries, cholera has caused seven pandemics and has been
responsible for tens of thousands of deaths. The research also showed that even during periods when it is
dormant, Vibrio cholerae, continues to thrive in brackish waters in both harmless and disease-causing
forms. Researchers have discovered that it is possible to predict with some accuracy future outbreaks of
cholera epidemics using satellite observations of sea surface temperature, sea surface height, and
chlorophyll in the water. Finally, the research also showed that bacteria such as Vibrio cholerae are
capable of communicating with other members of their species in order to coordinate their behavior in
response to cell density in a process known as quorum sensing that relies on the production and sensing of
one or more secreted signal molecules. A growing body of scientific studies has identified a complex
quorum sensing network in the Vibrio cholerae that may help researchers identify superior diagnostic and
treatment protocols in the future, but in the meantime, there have been some commonsense approaches to
treating water contaminated by Vibrio cholerae that reduce its incidence by almost half.
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Atherosclerosis and Antioxidants
Yehoshua Lewis

Abstract:
Cellular lipid oxidation is a known cause for the cascade leading to the formation of lipid laden
foam cells, which can cause of atherosclerosis. While statins and antioxidants have recently
come under question in the amelioration of atherosclerosis, Flavonoids have recently been
touted as a powerful antioxidant and suppresser of atherosclerosis. This paper will attempt to
show why statins and vitamin E have come under scrutiny, and how the desired effects of
Flavonoids can be attributed to the role it plays in increased paraoxonase-1 activity (a known
anti inflammatory associated with HDL), decreased C- Reactive protein activity, and increased
nitric oxide (NO) in endothelial cells among other factors.
Introduction:
Coronary artery disease (CAD) is the leading cause of death in the United States every year. According to
the Center for Disease Control and the National Center for Health Statistics, data for the year 2004
indicate that heart disease killed 652,486 people (U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES,
2008). This is nearly 100,000 more than the second leading cause of death in the United States, cancer.
Atherosclerotic plaque build-up in the arteries is the cause of CAD, and has been the primary focus of
scientists in search of a cure for CAD. Needless to say, much research has been done on finding the
causes of heart disease and developing drugs that inhibit its development. Other then pharmacological
products, there is a very large body of research into more natural remedies for atherosclerosis, including
antioxidants such as vitamin E that have been touted as providing protection against lipid oxidation.
Recently, however, there is a growing body of evidence that statins and antioxidant supplementation
may not be beneficial as thought. In contrast, Flavonoids, by operating under mechanisms different then
antioxidants and statins, offers new hope in the treatment of atherosclerosis.

Coronary Artery Disease:
While there are many factors that contribute to CAD, there are a number of factors specifically related
to atherosclerosis that play a key role in its development. Atherosclerosis is a progressive disease of the
arteries and is the result of plaque buildup in the arteries driven by the
uptake of cholesterol in artery walls (Medline Plus, 2007). Lipids are not
water soluble, and must rely on lipoproteins, produced in the liver and
small intestines, in order to be transported in the blood. By combining
lipids with lipoproteins, the lipids are able to be transported either to the
liver for elimination, or from the liver for the production of steroid
Figure 1. Dissected aorta with
hormones, bile salts, and for cell membrane repair. The two major
atherosclerotic lesions (Ewing,
lipoproteins involved in these functions are low-density lipoproteins
1972)
(LDL), and high-density lipoprotein (HDL); with LDL being responsible
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lipid transport from the liver, and HDL being responsible for transport of lipids to the liver for
elimination (Tortora & Derrickson, 2006).
Plaque formation begins with the aggregation of excess LDL in the inner layer of arterial walls
where the lipoproteins are subject to oxidation. In response, substances released by endothelial and
smooth muscle cells attract macrophages that ingest the oxidized LDL forming plaque. So much so, that
the macrophages take on a foamy appearance under the microscope (foam cells). Additionally,
lymphocytes (T cells) follow the macrophages into the arterial wall and increase the streaks in the
arterial walls. Subsequently, the macrophages cause the migration of the middle layer of the artery to
the surface of the plaque thus separating it from the bloodstream, but also narrowing the arterial
lumen. In the event that the cap over the plaque bursts, the T cells stimulate the foam cells to produce
tissue factor (TF), which ultimately leads to blood clot formation and possible obstruction of the
coronary artery, resulting in myocardial infarction (MI). Other factors currently being considered by
researchers include C-reactive proteins, which bind to damaged cells and assist in phagocytosis, clotting
factors, and the amino acid homocysteine that promotes platelet aggregation (Tortora & Derrickson,
2006).

Statins:
In order to treat atherosclerosis,
scientists have focused their attention on
reducing the amount of cholesterol
available in the bloodstream for oxidation
with the use of statin drugs.
In the 1960’s (Endo, 1992) scientists
discovered that when cholesterol is
completely eliminated from the diet, the
liver takes over and produces up to 82%
percent of the required cholesterol.
However, when cholesterol is added to the
diet the synthesis of cholesterol is almost
completely suppressed. They discovered
that the production or suppression of
cholesterol was in response to modulation
by HMG-CoA reductase which modulates
the inhibition of the Mevalonate pathway
of cholesterol synthesis (Figure 2). Through
modulating this enzyme they were able to
Figure 2. Mevalonate pathway of cholesterol synthesis
alter the production of cholesterol. Thus
(Chemistry Daily, 2007)
was born the first statin drugs. However,
there
are medical researchers who challenge the claim that statin drugs actually lower the risk factors for
myocardial infarction (MI). In a scathing review of studies purporting to show that by lowering
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cholesterol with statin drugs mortality rates are decreased, Kauffman (Kauffman, 2007) cites a study
carried out in New York City of a group of 2,277 people with the median age of 76 who were studied for
a period of ten years. What he found was that “The chance of dying was twice as great in subjects with
the lowest quartile of total cholesterol (TC) or LDL-C levels, compared with those in the highest
quartile”. Kauffman goes on to cite another study which shows that for men aged 35-57 “all cause”
mortality rates increased for those with a TC of <170 mg/dL and the risk increased further as TC
decreased to <140 mg/dL to the same levels seen for subjects with extremely high cholesterol
>300mg/dL. Kaufmann flatly states “Serum TC level is not even predictive of cardiovascular disease
(CVD) in men over the age of 47”. Kauffman is not alone in challenging the use of statins; the British
Medical Journal (Ravnskov et al., 2006) also challenges its widespread use, safety and efficacy. This
raises serious questions about how the medical community is facing the challenge of CAD.

Oxidation:
While statins focus on reducing TC as a remedy to the formation of atherosclerosis, there is
another very important juncture in the formation of atherosclerosis that has been the focus of research,
namely oxidative stress caused by free radicals and reactive oxygen species (ROS). ROS and free radicals
are injurious to lipids, DNA, and proteins if left unchecked by the bodies’ native defense mechanisms
(Davis, 1995). What are ROS and free radicals and why are they so important?
Examples of ROS include hydrogen peroxide (H2O2), hypochlorous acid (HClO). Free radicals
include superoxide anion (·O2−) and hydroxyl radical (·OH) (Davis, 1995). One source of the free radical
superoxide anion (·O2−) is that produced by the NADH/NADPH oxidase in macrophages during the
uptake of LDL (Runge, 1999). The superoxide is formed during the electron transport chain (ETS) when
the reduction of coenzyme Q in complex III forms the unstable Q·− radical which can leak electrons
directly to oxygen instead of cascading down the rest of the ETS thus forming superoxide radicals
(Holbrook, 2000).
Considering that 1% - 15% of O2 respired by mammals undergoes the superoxide anion (·O2−)
state (McGraw-Hill's Access Science), there is also ample opportunity to form undesired side reactions.
An example of a side reaction causing oxidative stress results when superoxide reacts with nitric oxide
(NO) to form peroxynitrite (·O2− + ·NO → ONO2−). Peroxynitrite then reacts as a strong oxidizing agent
with lipids, DNA, and proteins. Superoxide and NO individually can both be efficiently removed from the
body. Superoxide reacts with hydrogen in the presence superoxide dismutase (SOD) to form oxygen and
hydrogen peroxide (2·O2− + 2H+ → O2 + H2O2), which can then be converted by catalase to water and
oxygen. NO is rapidly removed by its diffusion through tissues into red blood cells. However, when
compared with SOD, the kinetics and thermodynamics during a reaction of NO and superoxide favor the
formation of peroxynitrite - resulting in the inevitable formation of a highly reactive oxidizing agent.
Peroxynitrite acts as a potent oxidizing agent towards LDL which then becomes the target for scavenger
cells and the formation of foam cells. Various studies have also shown that LDL can be oxidized by
peroxynitrite even in the presence of endogenous lipophilic antioxidants (Pacher et al., 2007).
Another source of oxidation is the Hydroxyl radicals (•OH) that are produced in the iron
catalyzed Haber-Weiss reaction. The Haber-Weiss reaction (Koppenol, 2001) was first discovered in the
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early 1930’s by Fritz Haber and Josef Weiss and proceeds as follows: Recalling that 1%-15% of O2
respired by mammals undergoes the superoxide anion (·O2−) state, we can propose the following
reactions:
Fe3+ + •O2− → Fe2+ + O2,
Followed by the Fenton reaction:
Fe2+ + H2O2 → Fe3+ + OH− + •OH,
For a net reaction of:
•O2- + H2O2 → •OH + HO- + O2.
Hydroxyl radicals are short lived in vivo, (Approx 10-9 s) and are highly reactive (Yan et al., 2005).
They also cannot be enzymatically removed because of its short half life and tends to react extremely
quickly with whatever is in its vicinity including: carbohydrates, nucleic acids, lipids, and amino acids.
The limitations of this process are inherent in that it requires Iron III in order to proceed, and the
blood plasma protein Transferrin is very effective at scavenging free iron, making it unavailable for
reduction. However, if there is a buildup of iron either due to dietary Iron overload or any other multiple
of diseases, it can outstrip the ability of Transferrin to perform properly and results in the production of
free radicals (Fouad, 2008).

Antioxidants:
As the oxidation of lipids form a key step in the formation of atherosclerosis, it should also lead
to the conclusion that “antioxidants” offer protection against lipid oxidation. However, the more
research that is being done, the more it becomes clear that exogenous sources of antioxidants have
questionable effects in vivo. The field of antioxidants is very broad and can be the subject of many
papers, but just to scratch the surface; antioxidants can be broken down into metabolite and enzymatic
categories as well as lipid soluble and water soluble. The difference between them is their mechanism as
well as site of action. For example: lipid soluble antioxidants act in cell membranes, and water soluble
antioxidants act in the blood plasma and cytoplasm. Lipid soluble antioxidants include vitamin E and
coenzyme Q (Q10). Water soluble antioxidants include ascorbic acid (vitamin C), glutathione, lipoic acid,
uric acid, and polyphenols (Flavonoids, tannins). Enzymatic antioxidants include the previously
mentioned SOD, catalase, as well as glutathione among others (Sies, 1997).
Vitamin E is a potent antioxidant and some research has shown that it can regulate HMG-CoA
reductase (Pal et al., 2003; Parker, 1993). Vitamin E is the name for a group of four tocopherols and four
tocotrienols, of which the most interesting to scientists is the α-tocopherol variety because of its high
bioavailability. Vitamin E is the main lipid-soluble antioxidant in the body and it works in cell membranes
where it prevents the propagation of free radical reactions (Herrera & Barbas, 2001).
Because vitamin E is lipid soluble, when absorbed vitamin E is packaged in Chylomicrons (large
lipoprotein particles) that are produced in the absorptive cells in the small intestine. They are then
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secreted via exocytosis into lacteals of the lymphatic system and delivered into the circulatory system at
the juncture of the thoracic duct and the left subclavian where they are transported to the liver. At the
liver, lipoprotein lipase (LPL) induces the unloading of some of the chylomicrons into the extrahepatic
tissue and the remainder chylomicrons transports the tocopherols into the liver. Here, “α-tocopherol
transfer protein" incorporates α-tocopherol into very low density lipoprotein (VLDL) the excess of which
is excreted into the bile duct. The α-tocopherol binded VLDL is then transported into circulation where it
is converted to LDL again by the action of LPL. The α-tocopherol is then taken up by the endothelial cell
membrane by the uptake of LDL via cell receptors (Herrera & Barbas, 2001).
Once in the cell membrane, α-tocopherol can act as a terminator to lipoprotein oxidation chain
reaction as follows:
Where “I” is the initiator and “LH” is the fatty
and L• is formed from the fatty acid

acid

I + LH → L• + IH [1]
Propagation continues as follows:
L• + O2 → LOO• [2]
LOO• + LH → LOOH + L• [3]
(See Figure 3)
Termination occurs when tocopherol “TO”
breaks the chain reaction:
LOO• + TOH → LOOH + TO• [4]
The tocopheroxyl radical then reacts with
another peroxyl radical to form tocopheryl
quinine (Q10) and thereby arresting the chain
reaction (Wolf, 2005).

Figure 3. The free radical mechanism of lipid
peroxidation

As with almost every system in the body, vitamin E does not function in isolation but is part of an
antioxidant network in which vitamin E can be synthesized from vitamin C and thiol redox cycles
involving glutathione and lipoic acid. (See attachment). Vitamin C has pro-oxidant properties as well
because of its ability to reduce metal ions via the Fenton reaction which can be a source of oxidative
stress. However, this is thought to be of minor significance as compared with its antioxidant properties
(FREI, 1999).
On the other front, research has shown that vitamin E, specifically tocotrienols, can modulate HMG-CoA
reductase similar way to that done by statins as discussed previously. (Parker et al., 1993)
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A number of studies showed this effect in mammals. In one study hyperlipidemic pigs given a
diet rich in tocotrienols showed a marked decrease in plasma concentrations of cholesterol,
apolipoprotein B (required in the formation of LDL), thromboxane B2 and platelet factor 4(both required
for blood coagulation), indicating a protective effect on endothelium and platelet aggregation (Qureshi
et al., 1991). There have been some conflicting results in similar trials in humans; however, those may
be attributed to plasma levels of tocotrienols and not to the efficacy of the compound (Packer et al.,
2001). It would thus seem that by ingesting vitamin E one would be able to take concrete measures in
arresting the propagation of atherosclerosis.
However, a recent Meta analysis by The Cochrane Collaboration - of studies proving the
remedial effects of vitamin E as well as other antioxidants - has not supported those results. Not only did
the ingestion of exogenous antioxidants not prove to be beneficial but has also shown to be detrimental.
The study included 232,550 participants who were “randomised to antioxidant supplements (betacarotene, vitamin A, vitamin C, vitamin E, and selenium) versus placebo or no intervention”. “A total of
17,880 of 136,023 participants (13.1%) randomised to antioxidant supplements and 10,136 of 96,527
participants (10.5%) randomised to placebo or no intervention died. In the analyses of the trials with low
risk of bias, beta-carotene, vitamin A, and vitamin E significantly increased mortality.” The study flatly
states that there is no evidence to support antioxidant supplementation. This study brings into question
the widespread use of antioxidants as a remedial and/or prophylactic compound for oxidative diseases
(Bjelakovic et al., 2008).

Flavonoids:
Increased consumption of fruits and vegetables is associated with reduced incidences of CAD
and other disease. The cause of this has been attributed in part, to antioxidant Flavonoids present in
these foods. The hypothesis in this case is that because after the consumption of Flavonoids there is a
marked increase in the antioxidant properties of blood plasma and it can play a direct role in the
prevention of lipid oxidation (Lotitoa & Frei, 2006). A clear example of this can be seen in the French
paradox, where despite the French consuming large amounts of red meat that are rich in unsaturated
fats they still develop lower instances of death from CAD then Americans. This has been attributed to
their consumption of red wine which is rich in Flavonoids (Ferrières, 2004).
Michael Aviram of the Technion faculty of medicine has done extensive research in the field of
pomegranate polyphenols (Flavonoids), and has made a very important contribution to the field. Among
the points studied three will be focused on: Antioxidant properties of blood plasma, paraoxonase-1
(PON-1)1 levels, and aortic stenosis - all after the ingestion of PJ. In one study (Aviram, et al., 2000), both
healthy human males and atherosclerotic E-deficient (E0) mouse subjects were fed PJ for variable
periods of time. The objective of the study was to determine what effect PJ consumption had on
lipoprotein oxidation, aggregation and retention; macrophage atherogenicity; platelet aggregation; and
atherosclerosis. The results of the study were striking. In humans, PJ consumption resulted in a decrease
in LDL susceptibility to aggregation (-11% ex vivo) and retention, also observed was serum PON-1
increased activity by 20% and that it also had a protective effect against LDL oxidation. Human plasma in
1

Paraoxonase1 (PON1) is an anti-inflammatory enzyme located on HDL.
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one case showed a decrease in lipid plasma peroxidation of ≤33%. In E0 mice, a 90% decrease in LDL
oxidation was observed as well as a 20% decrease in the uptake of LDL by peritoneal macrophages. Also
observed was a 44% decrease in atherosclerotic lesions and foam cells as compared with water fed
mice. Aviram et al., attributes the protective antioxidant effect of PJ to increased cellular glutathione
content, and states that the reduction of atherosclerotic lesions is directly related to the antioxidant
properties of PJ. Another study by Aviram of the long term effects of PJ consumption - in human
subjects with carotid artery stenosis (CAS) - on carotid lesions and changes in oxidative stress and blood
pressure had remarkable results. After 1 year control subjects showed a 9% increase in intima-media
thickness (IMT) as opposed to the PJ group that showed a 30% decrease in IMT. PON-1 activity increased
by 83%, serum LDL basal oxidative state was reduced by 90%, copper ion induced oxidation was reduced
by 59% and total antioxidant status (TAS) increased by 130%. Again, Aviram attributes these results to
the antioxidant characteristics of PJ polyphenols (Aviram, et al., 2004).
Jane Higdon, Ph.D. of The Linus Pauling Institute at Oregon State University takes a different
tack and claims that because the bioavailability of Flavonoids is very low, its antioxidant properties
cannot be attributed to the antioxidant properties proved in vitro. For example, the bioavailability of
Flavonoids in vivo is 100-1000 times lower than the bioavailability of vitamin C or glutathione and thus
has a very small antioxidant effect. However, it is available in concentrations that effect cell signaling
proteins. “Numerous studies in cell culture suggest that flavonoids may affect chronic disease by
selectively inhibiting kinases” including those related to growth factors. Higdon hypothesizes that it is
this property that protects against CAD by decreasing inflammation, decreasing vascular cell adhesion
molecule expression, increasing endothelial nitric oxide synthase (eNOS) activity, and decreasing
platelet aggregation (Higdon, 2005). Another study (Lotito & Frei, 2006), attributes the protective effect
of Flavonoids not directly to its antioxidant activity, but rather to the consequence of increased uric
acid.2 What is clear from all these studies is that it is not the antioxidant properties of Flavonoids that
directly protect against CAD but rather to a whole host of activities including: increased native
antioxidants such as glutathione, uric acid, modified cell signaling pathways, increased PON-1 activity,
and increased NO levels.

Possible Risks of Antioxidants vs. Flavonoids:
So then what really does account for the differences in Flavonoids and for example vitamin E?
What may be at play is as follows:
Vitamin E as well as having antioxidant properties is a pro-oxidant as well (Bowry et al., 1992).
For example: instead of the termination reaction by tocopherol to the oxidative chain reaction of lipids
as a final step:
LOO• + TOH → LOOH + TO• [4]
We instead form
2

Recent studies have implicated hyperuricemia as being a true risk factor in development of cardiovascular
disease (Jing Fang & Michael H. Alderman, 2000). However, nearly half of the bodies’ antioxidant activity is from
uric acid and in moderation may play a positive role.
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TO• + LH → TOH +L• [5]
This will then feed into the chain reaction
L• + O2 → LOO• [2]
LOO• + LH → LOOH + L• [3]
One study (Bowry, Ingold, & Stocker, 1992) has found that in aqueous solution, strikes between
the stable TO• and other radicals were found to take upward of 17 minutes, a time long enough that
even the most stable radical will find “`something to do’” i.e. propagate the chain reaction. The
termination of this reaction must then rely on two endogenous antioxidants vitamin C, as demonstrated
by the thiol redox cycles (Appendix 1), and ubiquinol (Q10H2, a reduced form of Q10) in the electron
transport chain. What can be inferred from this is that by ingesting vitamin E the body sets off a cascade
of endogenous antioxidants, in order to minimize the damage being incurred by vitamin E. While the
body does have the mechanisms of scavenging TO• how can making more of them by ingesting vitamin
E be advantageous? Essentially there is a delicate balance of electron radicals that are passed down a
cascade until they can be neutralized to a non reactive end product, and by adding more electron
radicals in the form of α-tocopherol it may have the effect of being counterproductive.

C - reactive protein and PON-1
By contrast, Flavonoids are effective not by acting as antioxidants but through modulating the
inflammatory response of oxidized cells.
The relationship between C - reactive protein (CRP) and Flavonoids illustrates this point. CRP is
found to be elevated during inflammatory response by the body, specifically, macrophages and T cells
release Interleukin-6 (IL-6) as a pro inflammatory to stimulate a response to tissue damage. CRP
production is then part of the acute-phase response to most forms of inflammation, infection, and tissue
damage. CRP levels by themselves cannot be used as marker for atherosclerosis, but they have been
positively correlated with CAD (Pepys & Hirschfield, 2003). Flavonoids have an inverse relationship with
CRP. One study using demographic data (Chun et al., 2008) found that the greater consumption of
Flavonoid rich foods, the lower the concentrations of serum CRP thus clearly indicating that Flavonoids
affect inflammatory response. Another study has also found an inverse relationship between levels of
CRP and levels of PON-1 expression. They found that “Higher levels of CRP seem to be generally
associated with low levels of PON1 activity” (Macknessa et al., 2006). Which should lead to the
conclusion that the atherosclerotic protection associated with Flavonoids is not related to an inherent
antioxidant activity but rather to other factors as mentioned.
Another study also found that polyphenols (i.e. Flavonoids) acutely enhanced nitric oxide bioactivity. NO
is necessary to maintain vasodilatation - the lack of which is implicated in increased risk of
cardiovascular disease (Anter et al., 2004).
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Conclusions:
In comparing the protective effects on atherosclerosis associated with statins, vitamin E, and
Flavonoids, there are many questions as to the ability of statins and vitamin E to afford real protection
against atherosclerosis. The data in many cases implicates these very compounds increased mortality
rates. By contrast, Flavonoids have shown themselves able to boost the bodies’ native antioxidants
including uric acid and glutathione, while at the same time reducing the inflammatory response to the
uptake of oxidized lipids. It could be that mother really knew best all along “an apple a day – really does
– keep the doctor away”. (Apple peals have been found to consist of 40% flavonols by weight (Łata &
Tomala, 2007 )).
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Excitoxicity in Retinal Ischemia and Treatment Using Non-Competitive Receptor Antagonists
Jacob Rube
Ischemia is defined as an inadequacy of blood flow to tissue. Ischemia can deprive tissue of
oxygen and metabolic substrates and it can also prevent the removal of waste products. If the ischemia
is maintained over enough time the tissue will lose its homeostasis and eventually die causing an infarct.
Retinal ischemia occurs when the blood supply to the retina does not meet the metabolic needs that are
required to sustain the retina. This can lead to retinal damage and severe vision loss. Ischemia is caused
by occluded blood vessels.
The retinal blood supply originates in the ophthalmic artery and branches into the different
sections of the retina. The external retina, which contains the cell bodies of the photoreceptors, is
provided with nutrients by the choroid blood vessels. The inner layer and ganglion layer, which contains
the ganglion bipolar and amacrine cell bodies, is nourished by the central retinal artery (CRA) (Brown,
1991).
Complete retinal ischemia occurs when the opthalamic artery is occluded. Major causes of
retinal ischemia are central retinal artery occlusion (CRAO), branch retinal artery occlusion (BRAO),
central retinal vein occlusion (CRVO), and branch retinal vein occlusion (BRVO). CRAO is caused by
either a thrombosis of the CRA or an embolisation of an artherosclerotic internal carotid artery (Brown,
1991). Ischemia caused by the CRAO leads to an infarction and loss of function of all the inner layers of
the retina while the outer layers of the retina including a portion of the inner nuclear layer remain intact
(Kincaid et al, 1998).
The CRA branches off into several different branches in order to perfuse the inner layer of the
retina. BRAO occurs when one or some of these vessels are occluded. BRAO has the same pathology
and risk factors of CRAO but affects more of a specific area of the inner retina depending on which
branch is occluded (Brown, 1991).
Venous occlusive diseases are more common clinically than arterial occlusions. The risk factors
for CRVO are similar to those of CRAO but also include an elevated intraocular pressure (IOP) or an
underlying hematological disease (Mitchell et al., 1996).
Ionotropic Receptors
Ionotropic receptors are a group of transmembrane ion channels that are opened or closed in
response to the binding of a chemical messenger. NMDA (N-methyl-D-aspartic acid), AMPA (α-amino-3hydroxyl-5-methyl-4-isoxazole-propionate), and kainite receptors are ionotropic receptors in neurons
that are activated by glutamate which is a main neuron neurotransmitter (Digledine et al 1999). NMDA
receptors are responsible for regulating the influx of calcium and other ions in the cell. Normally the
channel is blocked by Mg2+ ions (Eby and Eby, 2006). Under normal circumstances a nearby AMPA
receptor is activated during resting polarization by glutamate, which starts depolarization. This
depolarization spreads to the NMDA receptor and it releases the Mg2+ ions. Once the NMDA receptor is
open glutamate will activate the receptor, which causes an influx of Ca2+ and Na+. Ca2+ is used by the cell
Jacob Rube, BS ’10 graduated Touro with a degree in Biology Honors. He is planning on attending medical
school in the fall.
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to activate metabolic pathways and reactions in the cell.
Kainate receptors are not as well understood as other receptors but its conductance is very
similar to that of AMPA receptors.
Metabotropic Glutamate Receptors
Metabotropic receptors differ from ionotropic receptors, like NMDA and AMPA, in that instead
of activating an integral ion channel they activate secondary messengers usually G-proteins, which
activate ion channels on the plasma membrane. To date eight distinct subtypes of metabotropic
glutamate receptors (mGluRs) have been identified and separated into three groups based on function
and sequence homology (Thoreson and Witkovsky, 1999). Group 1 mGluRs (mGlu1 and mGlu5) are
usually located postsynaptically and enhance the cell’s excitability by mobilizing intracellular Ca2+ and
activating protein kinase C, which leads to several signal transduction pathways.
Group II (mGlu2 and mGlu3) and Group III (mGlu4 and mGlu6-8) are typically found
presynaptically. The transduction process of these receptors involve a negative coupling with adenylate
cyclase and their activation causes a reduction in glutamate release which lowers synaptic excitability
(Nicoletti et al, 1996).
Ischemic Cascade
On the cellular level death from ischemic attack is brought about by many factors. The start of
the cascade comes from the lack of oxygen and glucose supply. This leads to decreased rates of
glycolysis and oxidative phosphorylation, which causes levels of ATP to fall (Lipton, 1999).
The main impact of the decrease of ATP in the neuron is the inhibition of the Na⁺/K⁺-ATPase
transporter, which is a transporting enzyme on the cell membrane. The main function of this enzyme is
to restore the resting potential of the neuron after it has been hyperpolarized from the release of excess
potassium. When the neuron becomes hyperpolarized the Na⁺/K⁺-ATPase actively transports sodium
ions out of the cell and potassium ions inside the cell to restore the neuron to its resting potential so
that it can depolarize and make an action potential. Once this enzyme is inhibited the voltage
dependent Mg2+ on the NMDA (N-methyl-D-aspartic acid) receptors becomes loose which allows for an
excess uptake of calcium by the cell (Zeevalk and Nicklas, 1992). Ionotropic AMPA (α-amino-3-hydroxyl5-methyl-4-isoxazole-propionate)/kainite type glutamate receptors also become more activated which
leads to an influx of ions and osmotically obligated water which can lead to cell lysis. The inhibition of
the Na⁺/K⁺-ATPase is the cause of the hyper activation of these receptors.
These receptors are activated by glutamate, which is an extracellular neurotransmitter in the
brain. During ischemia, through some proposed mechanisms, which will be elaborated later, there is an
increase in extracellular glutamate levels, which in turn activate the now active receptors during
reperfusion, which leads to cell death as will be explained later on in this paper. This rise in glutamate
levels has been documented in several studies (Neal et al, 1994; Shimada et al, 1993).
The early mechanism proposed for the increase in extracellular glutamate levels was that after
the opening of the Ca2+ channels there would be an increase in exocytotic neurotransmitter release
through normal metabolic pathways. This is because an increase in Ca2+ in a cell will cause an increase in
cell metabolism. However, due to the depletion of ATP in the cell, this mechanism cannot really account
the very high levels of glutamate because of the lack of energy available for this process to occur
(Nishazawa, 2001).
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The main candidate for an alternative mechanism is the reverse transport of glutamate
transporter proteins. The transport of glutamate into the cell in order to prevent excessive
depolarization is not driven by ATP but rather by the Na+ gradient inside the cell and the concentration
of K+ and pH-changing anions out of the cell (Barbour et al 1998). When ischemia occurs and Na⁺/K⁺ATPase begins to reduce in activity, the Na+ gradient is decreased and the K+ accumulates in the
extracellular space, which may reverse glutamate uptake (Attwell et al, 1993). This mechanism was
proposed when it was noticed that there was an increase in extracellular glutamate in anoxic conditions
(David et al, 1988). Other studies have shown that glutamate levels are increased when there is either
an increase in extracellular K+ on intracellular Na+ (Barbour et al, 1991).
Normally glutamate is taken up by glia and converted by glutamine synthetase into glutamine
and returned back into the neural soma (Thoreson and Witkovsky, 1999). Ischemia lowers the ATP
levels in glia and causes a decrease in the conversion of glutamate. This causes an increase in the
glutamate/glutamine ratio, which may also lead to extracellular glutamate (Oliver et al, 1990).
Once the cell constantly becomes depolarized excess calcium enters the cell and sets off many
cascades that lead to cell death. Among the most critical are free radical production and nitric oxide
(NO) synthesis, activation of phospholipase A2, DNA cleavage, activation of proteases, and subsequent
damage to cytoskeleton. One of the main influences of the high calcium level is the formation of
superoxide radicals (Bonne et al, 1998). Calcium activates a dependent protease calpain, which converts
xanthine dehydrogenase to xanthine oxidase. Upon reperfusion, this enzyme converts hypoxanthine to
uric acid, which results in the release of superoxide radicals (Chan, 1996). One of the major ways that
superoxide damages the cell is that it attacks unsaturated fatty acids which lead to lipid perioxidation of
membranes (Doly et al, 1984). This will result in loss of membrane fluidity, cell swelling, oedema, and
feed forward production of more oxygen-derived radicals. There are many other pathways that cause
cell damage that stem from the increase in calcium ions, which can lead to the activation of procaspases
which leads to apoptosis.
The following figure illustrates the different steps in retinal ischemia.
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Fig. 1. Summary of hypothesised key events in the process of ischemic retinal neurodegeneration. An interruption
in the supply of blood to the retina leads to tissue ischemia which causes rapid failure of energy production and
+ +
subsequent events as outlined in the figure. Key steps include the failure of the Na /K –ATPase pump, membrane
depolarisation, cytoplasmic accumulation of sodium and calcium ions and the formation of destructive free radical
species. The summed cellular response of these processes, if left unchecked, is cell death. This can occur by the
classical and rapid necrotic process or by longer-duration apoptosis (Osborne et al., 2004).

Retina Damage in Ischemia
Glutamate is the major excitatory retinal neurotransmitter and is released in vivo, by
photoreceptors, bipolar cells, and ganglion cells. The photoreceptors have only shown susceptibility to
be damaged after the rest of the retina has shut down and studies have shown that ischemia has less
effect on the outer layer of the retina than the inner layer of the retina (Peachey et al, 1993). The
reason that photoreceptors are less sensitive remains unknown. One possibility is that their
mitochondria have a high-density inner segment and is maintained on a smaller pO2. In addition there is
more neuroglobin in photoreceptors (Schmidt et al, 2003) which helps maintain oxygen levels inside
cells in the cerebral and peripheral nervous system. Neuroglobin has a high affinity for oxygen and
provides extra oxygen for cells under ischemic attack or in hypoxic conditions.
Ganglion cells are highly susceptible to ischemic attack and all known retinal ischemic paradigms
have been described as a loss of ganglion cells (Akiyama et al, 2002; Goto et al., 2002). Ganglion cells
express both the NMDA receptor and kainite type receptor (Fletcher et al., 2000), which are activated by
the excessive glutamate levels, which lead to chronic depolarization. Amacrine cells also contain these
receptors and are susceptible to ischemic attack through the same mechanism. Both amacrine and
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ganglion cells have many metabotropic glutamate receptors which also may be the reason for their
susceptibility to ischemic attack (Osborne et al., 1991).
What sets ischemic attack on the retina different from the brain, is the fact that the retina has a
much longer tolerance time. A few minutes of cerebral ischemia in the human results in widespread
injury, but it has been demonstrated that a primate retina can suffer up to 100 minutes of CRAO without
permanent injury (Hayreh and Weingeist, 1980). This can be explained by the fact that retina contains
about 100 times more neuroglobin and other energy reserves that can be used up during the hypoxic
conditions of ischemia (Schmidt et al., 2003).
Alternatively there is a “no flow” phenomenon that may explain this difference (Fischer et al.,
1977). This phenomenon is involved in where the rigid cranium compresses the microvasculature in a
swollen brain, which causes an ongoing ischemic attack even though macroscopic blood flow is restored.
In retina ischemia oedematous retina does not compress the microvasculature since there is a vitreous
cavity to expand into. This large amount of time before irreversible retina destruction has allowed for
many studies to be done on how to reverse ischemia or minimize ischemic damage.
Treatment Using NMDA Antagonists
It has been shown in vivo that with the addition of NMDA antagonist one can protect a neuron
from ischemic attack (Lombardi et al., 1994). Competitive antagonists although shown to be effective,
will only likely be used in experimental studies. These receptor antagonists may not be useful in man
due to long lasting actions, which can affect neural processes. However, major interest has arisen in the
use of non-competitive NMDA antagonists. This is because these compounds have shown the ability to
cross blood retinal barrier and it is believed that such drugs will block the toxic actions NMDA receptors
in ischemia and yet sustain NMDA receptor functions in the brain to maintain cognitive and memory
processes.
This evidence supports the idea that using a NMDA antagonist one can slow down or even stop
ischemic attack. One particular antagonist that has been showing great results is dextromethorphan.
Dextromethorphan is an antiussive drug and is used in over the counter cough and cold medicines and it
has been shown to have uses in pain relief (Bem and Peck, 1992).
Evidence on retina health after ischemic attacks were obtained through Electroretinography
(ERG), which is a test in which electrodes are attached to the eye and it measures the activity of the
retina by measuring the electrical activity of the retina in response to light. The ERG will contain an awave (initial negative deflection) followed by a b-wave (positive deflection).
In studies done using dextromethorphan while invoking a retinal ischemic attack, results show
that retinas that were treated with dextromethorphan were able to maintain function better after the
restoration of blood flow than retina that were not treated with dextromethorphan. In 30 and 60
minute strokes, rats that were treated with dextromethorphan had a better recovery time and less
retinal damage than the mice not treated with the drug (Cao et al., 1994). However, caution is
necessary when studying this drug because it may be that dextromethorphan increases cerebral blood
flow and/or decrease cerebral metabolic requirements instead of blocking the ischemic stroke
pathology (Osborne et al., 2004). Also it could be that dextromethorphan was only protecting the rat
retinas from the increased pressure brought on by the induced stroke in the rat and therefore may not
be potent for clinical use (George et al., 1988).
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Dizocilpine (MK-801), another NMDA antagonist has shown better results in stopping retinal
ischemia (Lam et al., 1997). However, it’s neurotoxic side affects causes reduced brain function and
make it almost impossible for clinical use. Also, the lowing of ischemic affects may be due to other
metabolic side affects of MK-801 in that it lowers CNS temperature, which lowers the oxygen
consumption during ischemia (Chi et al., 1991).
Other NMDA antagonists have been used in studies for retinal diseases. They include eliprodil,
which blocks at the polyamine site of the NMDA receptor (Biton et al., 1994), fliurpitine, and
memantine. Even though it has been well noted that NMDA receptor antagonists block excitoxicity, the
therapeutic use should be questioned because of the negative affects that they can have on the patient.
It has been suggested that memantine may be better tolerated than other NMDA antagonists because
of it low affinity for the NMDA channel (Parsons et al., 1993).
Conclusion
In conclusion, ischemia in the retina, if left untreated, is almost certain to cause permanent
damage to the retina and eventually to severe vision loss. Ischemia unleashes a cascade starting with
the lack of oxygen, which causes the Na+/K+ ATPase to lose function, which leads to hyper-activation of
glutamate receptors. The lack of oxygen also leads to an increase in
extracellular glutamate, which
can cause two forms of death. Glutamate can lead to an influx of ions, which will be followed by water
under osmosis and cause cell lysis. Also, glutamate allows an increase in the uptake of calcium ions,
which activates mechanisms to form radicals that can activate apoptotic mechanisms in the cell.
One proposed way of treating retinal ischemia is to administer non-competitive NMDA
antagonists, which should block the entrance of calcium into the cell. The interest in using these
chemicals has been big because they can cross the blood retinal barrier and are believed to not severely
impair cognitive processes. Also, they can be administered after the ischemic attack has already begun.
However, clinically there have been no real breakthroughs because of concerns that in vivo experiments
only exhibit positive results because of other mechanisms involved and the concern of damaging normal
receptor function.
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The Nerve Cells of the Retina
Penina Winkler
Abstract
The visual pathway in the retina consists of a chain of different nerve cells. Light first travels
through all the layers until it reaches the photoreceptor layer, the rod and cone layer. Rods and cones
use photopigments, which contain opsin and a chromophore, to help them convert light into energy.
This energy is then passed on to the horizontal and bipolar cells. Horizontal cells prevent the
hyperpolarization of peripheral rods and cones if needed, and they receive color-coded signals from
cones that they then continue along the optic pathway. Bipolar cells can be divided into rod bipolar cells
and cone bipolar cells. Cone bipolar cells can be further subdivided into midget cone bipolar cells, which
only contact one cone cell and one ganglion, and diffuse cone bipolar cells, which can contact several
cone and ganglion cells. Bipolar cells can either hyperpolarize or depolarize with light, and they pass
their signal on to amacrine cells or ganglion cells. Amacrine cells provide inhibition to the visual
pathway, either through feedback inhibition on the bipolar cells or feedforward inhibition on ganglion
cells. A1 amacrine cells provide long-range inhibition of ganglion cells. Indoleamine-accumulating
amacrine cells provide a reciprocal response to bipolar cells, preventing them from hyperpolarizing so
that their signal does not continue. AII amacrine cells receive input from bipolar cells and output the
signal to different bipolar cells to be transmitted to ganglion cells. Ganglion cells, the last nerve cells in
the visual pathway, only receive input when light hits the part of the receptive zone that produces a
discharge when stimulated by a light source. Ganglion cells are specialized to detect movement in a
specific direction. This prevents the brain from receiving unnecessary information. EphrinA and EphrinB
are two molecules that form gradients that lead the ganglion cells to their specific destination in the
brain. Magnocellular (MC) ganglion cells and intrinsically photosentive retinal ganglion cells (ipRGCs) are
specific types of ganglion cells, with MC cells dominating during fixational eye movements, and ipRGCs
working as circadian photoreceptors like rods and cones, contributing to light-stimulated effects on the
body. Müller cells are not part of the visual pathway, but they provide support for the retina and
regulation of nutrients and molecules, as well as perform
many other functions in the retina.

(Kolb H. et. al. 1996)
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Introduction
The eye is a complex sensory organ which receives visual images and carries them to the brain.
When a light stimulus is initiated, the light coming into the eye touches the three tunics, or layers, of the
eye; the outer tunic, the middle tunic, and the inner tunic. The first tunic is the outer tunic (colored
white in diagram above), which consists of the sclera and the cornea. This layer provides protection to
the inner structures of the eye, and maintains the shape and consistency of the eyeball. The sclera is the
part of the outer tunic that covers the back of the eye, while the transparent cornea, a clear dome,
covers the front of the eye. (Szaflarski, D.M. 1999) The aqueous humor is a thin, watery fluid that fills
the space between the cornea and the iris of the middle tunic. The middle tunic is also called the uvea
(colored blue in diagram above), which reduces the reflection of light and contains blood vessels. The
back of the uvea, located under the sclera, is called the choroid. The ciliary bodies of the uvea cause the
iris to constrict or dilate to control the amount of light entering the pupil, the hole through which light
enters the lens. After light moves through the lens, it enters the vitreous humor and then the inner
tunic. The inner tunic is the retina (colored red in diagram above), the most important part of the eye in
terms of sight. The retina is the part of the eye that receives light impulses and converts them into
energy that can be passed on to the brain. (Montgomery, T., 1998) Therefore, to understand how a
human being is able to see, one must look into the inner workings of the retina, the most vital part of
the visual process. The purpose of this paper is to describe the functions of the different types of cells
found in the retina, and how each contributes to sight.
The retina has ten layers; the pigmented epithelium, the inner and outer segments of rods and
cones, the outer limiting membrane, the outer nuclear layer, the outer plexiform layer, the inner nuclear
layer, the inner plexiform layer, the ganglion cell layer, the nerve fiber layer, and inner limiting
membrane. By following the nerve cells through these layers, one can see the pathway that the
converted energy of light impulses takes to reach the optic nerve, which leads to the brain.
The pigmented epithelium is located on the external retinal wall, providing vitamin A, or retinal
to the photoreceptors that it contacts. The layer of the rods and cones is where the conversion of light
to energy takes place. The junctions between the rods and cones and the Müller cells make up the outer
limiting membrane, which forms a blood retina barrier, isolating the inner layers of the retina from
harmful substances in blood. The outer nuclear layer contains the nuclei of rods and cones. The outer
plexiform layer is the layer in which the axons of the cones and rods synapse with the dendrites of the
bipolar and the neurites of horizontal cells. The inner nuclear layer contains the nuclei of the bipolar,
horizontal, and amacrine cells. In the inner plexiform layer, the axons of bipolar cells synapse with the
neurites of amacrine cells and the dendrites of ganglion cells. In this layer, the neurites of amacrine cells
also synapse with ganglion cell dendrites. The ganglion cell layer contains the nuclei of the ganglion cells,
which then converge in the nerve fiber layer. The inner limiting membrane is made up of Müller cells,
which form a barrier between the retinal nerve cells and the potentially harmful substances in the
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vitreous humor. (Caceci T., 2001) Each type of cell in the pathway has its own functions which help to
increase the accuracy and speed of vision.

(Kolb H. et. al. 1996)

(Gurney P.W.V. 1999)
Rods and Cones
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When light hits the retina, it first goes through all the layers of the retina before the cells begin to
respond. This is because the photoreceptor cells, the rods and cones, are located on the outer region of
the retina, furthest from the lens.

(Juelich F., 2004)
Both rods and cones are made up of two segments, the outer segment and the inner segment.
The outer segment exhibits flat, membranous disks containing a photo pigment. The disks are infoldings
of the plasma membrane that become narrower as they move away from the modified cilium, the
connecting region between the inner and outer segments. These disks are produced in the inner
segment and are transported by kinesins and cytoplasmic dyneins along microtubules toward the outer
segment across the bridge of modified cilium. The disks are continuously being renewed; the used disks
are phagocytosed by cells of pigmented epithelium. The inner segment is abundant in mitochondria;
mitochondria are involved in the synthesis of adenosine triphosphate, the Golgi apparatus, and
endoplasmic reticulum. (Caceci T., 2001)
Rods contain the pigment rhodopsin, which functions during night vision, while cones contain
iodopsin, which helps to see more accurate detail and color. There are three types of cone cells, which
respond to different regions of the spectrum, discriminating the colors blue, green, and red. There are
other differences between the two cells. In the cone cell the outer segment is conical, while in the rod
cell it is cylindrical. The cone cell axon ends in a cone pedicle, a large, conical, flat end, which is thicker
than the rod spherule, small round enlargements of the axon. Both rod and cone synapse with the
cytoplasmic processes of bipolar and horizontal cells. (Kolb H. et. al. 1996)
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Rods and cones are transducers; they convert light into electrical or neural energy. In order for
this to occur, the rods and cones need photopigments. The protein opsin and a chromophore, retinal,
constitute the photopigments of the rods and cones. The chromophore is needed so that color will be
absorbed; without the chromophore, the photoreceptor would just absorb UV light. The photopigments
are needed to provide the energy required to cause an electrical change in the membrane of the rod or
cone that will be propagated from the point of absorption of the light to the rod spherule. The electrical
change occurs when the photoreceptor is bleached, the process in which the photopigment absorbs a
photon and changes chemically into its constituents, which are less sensitive to light. In darkness, the
rod and cone cells are depolarized, and they continuously release the neurotransmitter glutamate to the
bipolar cell; this inhibition of the bipolar cell is known as the “dark current.” As light hits the
photopigment, retinal is activated. This causes the opsin to activate transducin, which activates
phosphodiesterase. Phosphodiesterase breaks cyclic guanosine monophosphate down into guanosine
monophosphate. The cell membrane becomes hyperpolarized, and glutamate is no longer released to
the bipolar cell. This causes the bipolar and horizontal cells to hyperpolarize as well, and the message
continues along the chain. (Stockman A. et. al. 2007)

(Stockman A. et. al. 2007)

Horizontal Cells
Horizontal cells are one of the intermediaries between photoreceptors and ganglion cells. Their
nuclei are found in the inner nuclear layer, and their neurites, their cytoplasmic processes (they do not
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have axons or dendrites), attach to the rod spherules, cone pedicles, the dendrites of bipolar cells, and
the neurites of other horizontal cells in the outer plexiform layer. One horizontal cell synapses with
more than one type of cell at the same time, because each neurite can have many branches. Because
the horizontal cell has many branches and can reach many cells horizontally across the outer plexiform
layer, it allows one part of the retina to influence the other part’s activity. Horizontal processes are in
close proximity to retinal capillaries, and there may be neurovascular coupling between the processes
and the capillaries. Such intimate contact with the capillaries was previously thought to be a
characteristic of Müller glial cells and astrocytes; some species of horizontal cells have glial proteins
(glial fibrillary acidic protein or vimentin), and both horizontal cells and glial cells develop from the same
precursors during retinal development. (Mojumder D.K. 2009)
The membrane of the horizontal cell contains ionotropic glutamate receptors which need direct
activation by glutamate. The receptors are ionotropic because the receptor and the ion channel form
one complex, so they directly gate ion channels; they open ion channels when receiving glutamate.
Glutamate release from rods and cones causes glutamate to be received by the glutamate receptor,
which then causes the cell to be depolarized; a decrease in glutamate, a response to light, causes
hyperpolarization of the cell. The horizontal cells provide feedback control of photoreceptor synaptic
output. They perform negative feedback to photoreceptor synaptic terminals at the first synapse of the
visual pathway. The cell exerts a restraining influence on the junction by stopping the response from
continuing to the bipolar cells. It is widely believed that these restraining influences only occur on cones,
not rods. The role of horizontal cells on the rod pathway is unclear. (Bloomfield S.A. et al 2001)
The three different types of cones transmit their effects to bipolar and horizontal cells. In many
experiments conducted on horizontal cells, the cells showed two types of potentials when recorded,
color and luminosity. The color types of cell give an opponent type of response; the colors blue and
yellow have opposing effects in some cells, while red and green have opposing effects in other cells. The
blue-yellow cell has connections with blue and red and green cones, while the red-green cell has
connections with only red and green cones. The transmission of different wavelengths to different types
of horizontal cells leads to a detailed color-coded message that is passed on to the optic nerve.
(Burkhart D.A. et. al., 1978)

Bipolar Cells
Bipolar cells, like horizontal cells, are intermediaries between photoreceptors and ganglion cells.
Their nuclei are found in the inner nuclear layer, their dendrites contact photoreceptor cell terminals in
the outer plexiform layer, and their axons stretch into the inner plexiform layer to contact ganglion cells.
Bipolar cells can be subdivided based on the photoreceptor cells they synapse with. Therefore, there are
rod bipolar cells, which synapse with rod spherules only, and there are cone bipolar cells, which synapse
with cone pedicles only. The cone bipolar cells can be further divided into the midget cone bipolar cell
and the diffuse cone bipolar cell. The midget bipolar cell synapses with a single cone cell, and has only
one axon which contacts a single ganglion cell, which is continuous with the optic nerve. In reality, a true
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one to one connection in the retina does not exist, because although one midget bipolar cell can contact
one cone pedicle, a diffuse bipolar cell can attach to the same cone as well. Also, horizontal and
amacrine cells contact midget bipolar cell, ganglion cells, and cones laterally. Because of the
interconnections between the nerve cells, no optic nerve fiber actually carries messages from one cone,
but because of the midget bipolar cell pathway, an increased level of acuity is reached when a less dilute
message reaches the optic nerve. It is this pathway that causes cone vision to be more accurate than rod
vision. The diffuse cone bipolar cell contacts up to seven cone cells at one time and synapses with many
ganglion at a time. The diffuse cone bipolar cell has wider input and output pathways than the midget
bipolar cell. (Kolb H. et. al. 1996) Cone bipolar cells can also be divided into invaginating cone bipolar
cells, whose dendrites penetrate the synaptic invaginations of the cone pedicles, and flat cone bipolar
cells, whose dendrites remain superficial and establish basal contacts. (Bloomfield S.A. et al 2001)
One rod bipolar cell can synapse with up to fifty rods. This causes the same effect if there are
one hundred quanta falling on a single rod or one quanta falling on one hundred rods. There is no
difference, because ultimately the same signal will reach the bipolar cell. Also, if a high density of rods
converges on a single bipolar cell, and a high density of bipolar cells converges on one ganglion cell,
there are many signals falling on one ganglion cell. During night vision, the power of bipolar and
ganglion cells to collect impulses increases; the impulses were previously inhibited by higher
illumination of the retina. This causes an increase in the amount of signals on the ganglion cell; it is
because of this large amount of converging that during night vision, visual acuity is decreased. With so
many impulses entering the ganglion cell, the cell can not interpret all the impulses to the degree where
vision would be as accurate as it is during normal vision. (Kolb H. et. al. 1996)
When there is a decrease in glutamate levels as a response to light, the photoreceptor cells
depolarize, which causes the bipolar cell to depolarize or hyperpolarize depending on whether the cell is
an ON-bipolar cell or an OFF-bipolar cell. With decreased glutamate, an ON-bipolar cell depolarizes and
an OFF-bipolar cell hyperpolarizes. In the rod vision pathway, rod bipolar cells contact two types of
amacrine cells, which serve as interneurons in the transmission of light signals in night vision. These
amacrine cells, AII amacrine cells, then transmit the signal to cone bipolar cells, the final conduit to the
ganglion cell during rod vision. Cone bipolar cells are used during rod vision, revealing that the rod and
cone circuits are intertwined. (Bloomfield S.A. et al 2001)

Amacrine Cells
Amacrine cells are interneurons with nuclei in the inner nuclear layer. They have one neuritic
process which branches and connects to the axons of the bipolar cells and the dendrites of the ganglion
cells in the inner plexiform layer. Like horizontal cells, amacrine cells connect to bipolar and ganglion
cells horizontally, so that one area of the retina can impact another area. All amacrine cells display
dendritic and somatic impulse activity. This impulse activity is important, as it performs feedforward
inhibition on ganglion cells and feedback inhibition on bipolar cells via action potentials. The amacrine
cell exerts a restraining influence on certain junctions of the retina, reducing the spread of messages. In
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relation to the ganglion dendritic tree, bipolar cells make up the center of the receptive field, while
amacrine cells make up the periphery. When the amacrine cells exert an inhibitory action, the bipolar
cells in the central zone of the field are prevented from responding to the receptors, and the message is
not sent to the ganglion cell. (Kolb H. 2003) The inhibition caused by the amacrine cell has two distinct
modes, local and global. If the action potential can not be propagated down the cell to the dendrites
then they provide local inhibition. If, however, the action potential invades the entire dendritic tree, it
provides global inhibition. Amacrine cells can be divided into different types based on the size of their
dendritic spread, dendritic sublamination patterns, neurotransmitter subtypes, and variations in the
morphological features. (Royer A.S. et al 2007) There are three specific types of amacrine cells discussed
in this paper; A1 amacrine cells, indoleamine-accumulating cells (IAC), and AII amacrine cells.
The A1 amacrine cell is a spiking, axon-bearing interneuron in the retina, with thick, spiny, and
highly branched dendrites in the inner plexiform layer. A1 cells receive inputs to their dendrites that
cause depolarization, which initiates an action potential. The action potential then propagates down the
axon and crosses the retina. The A1 cells have extensive branching, indicating that they serve a global
function in vision processing. A1 cells are mediators of long-range inhibition of ganglion cells in response
to global image motion. Their spiking output structures may be a key element in long range lateral
inhibition of the retina. The A1 cells have center-surround receptive fields which combine inputs from
ON bipolar cells and OFF surrounds and OFF bipolar cells and ON surrounds. Because amacrine cells are
stimulated by both ON-center and OFF-surround, and OFF-center and ON-surround, the inhibition of
amacrine cells is postsynaptic to all bipolar cells, regardless of their responses to stimulation. A1
amacrine cells provide inhibitory feedback on all bipolar cells. (Davenport C.M et al 2007)
IAC amacrine cells, also known as A17 amacrine cells, account for half of the rod bipolar cell
output. IAC cells receive input from rod bipolar cells and multiple types of amacrine cells in the inner
plexiform layer. The sole postsynaptic target of IAC cells is rod bipolar cells; IAC cells return reciprocal
synapse back onto rod bipolar cells. This arrangement causes an interconnecting of rod bipolar cells in
the inner plexiform layer. IAC amacrine cells contain GABA, and there are GABA receptors present on
the axons of the rod bipolar cells; this indicates that the IAC cell has an inhibitory feedback function in
the reciprocal synapse. (Bloomfield S.A. et al 2001)
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(Kolb H. et. al. 1996)
AII amacrine cells function during rod and cone vision. In scotopic vision, night or dim-lit vision,
AII cells are major carriers of rod signals to ganglion cells. They receive input from rod bipolar cells, but
do not return the signal back to rod bipolar cells. Instead, the cells form homogenous gap junctions with
other AII cells near the site of the synapse of the rod bipolar cell. The AII cells then synapse with the
axon terminals of cone bipolar cells. AII cells also receive input from cone bipolar cells, indicating that
the cells are also part of the photopic, normal light vision. AII amacrine cells are in dense population in
most of the retina because they are a key element in the visual process. (Bloomfield S.A. et al 2001)

Ganglion Cells
Ganglion cells are the last retinal cells in the visual pathway; their axons form part of the optic
nerve. The nuclei of the ganglion cells are in the ganglion cell layer, and their dendrites extend into the
inner plexiform layer and synapse with bipolar cells. There are two types of ganglion cells; midget
ganglion cells, which synapse with only one bipolar cell, and diffuse ganglion cells, which synapse with
several bipolar cells. The midget ganglion cells receive impulses from midget cone bipolar cells, so they
are part of the cone visual pathway only. (Kolb H. et. al. 1996) The ganglion cell receives information
from all stages in the visual pathway. The ganglion cell can convey signals that drive the circadian and
pupillomotor systems by combining the rod and cone photoresponses, as well as its own
photoresponses. (Dacey D. M. et al 2005)
The ganglion cell response is not switched on and off as the light source is switched on or off.
When the light source is emitting light to the central zone of the receptive field, a discharge is produced.
The periphery zone of the receptive field has the opposing response, and will only produce discharge if
there is no light. The center and the periphery usually have opposite responses in terms of color; for
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example, an off-response to green in the surrounding area and an on-response to red in the center of
the field. A simultaneous stimulation of red in the center and green in the periphery would elicit no
response, because the on-response of the center is cancelled out by the off-response of the periphery.
This opponent organization serves to enable the retina to emphasize different colors; the involuntary
movements of the eye in normal vision keeps shifting the boundaries of the center and the periphery,
causing different colors to be seen. Another effect of this inhibitory organization is to prevent unneeded
information from reaching the brain. There are about one million optic nerve fibers, and if all of them
were discharging information at once, the brain would have too many messages to decode. This
mechanism helps to cut down the amount of information the brain needs to process. (Encyclopædia
Britannica 2009) Another method that some ganglion cells use to decrease the amount of action
potentials it sends to the optic nerve is to respond to light moving only in a specific direction. When an
object moves in the ganglion’s preferred direction an excitatory impulse occurs. When the object moves
in the opposite direction, however, both excitatory and inhibitory impulses occur, effectively canceling
each other out. (Barinaga M. 2000)
Each ganglion cell carries a chemical tag that corresponds to chemicals in the tectum, the dorsal
part of the midbrain; these chemicals convey positional information to the cell. The ganglion cell
interprets this information and responds by connecting to a specific point in the brain. There are two
gradients in the ganglion cell pathway to help the axons of the ganglion cells hit their target position
exactly. The gradient made up of molecules in the tectum called EphrinA specifies where the ganglion
axons will end up in terms of the anterior-posterior axis. The gradient made up of molecules called
EphrinB specifies where along the medial-lateral axis the axon will end up. If an axon is moving in a
direction that is either medial or lateral to its destination, it projects branches towards the destination.
The EphrinB regulates this branching. The Wnt3 protein counteracts the pull of EphrinB towards the
most medial tectum, so the lateral tectum is not empty. The gradient of Wnt3 is along the same
direction as EphrinB’s gradient, but is a repellent gradient. Ryk, the receptor for Wnt3 on the ganglion
on cell, is expressed in ganglion cells in the same direction as EphrinB, proving that it is Wnt3 that
provides the repellent gradient. (Liqun Luo 2006)
A specific type of ganglion cell, the magnocellular (MC) ganglion cell, was experimented on and
found to be responsible for the visual illusions that are seen during fixational eye movements. When one
stares at a stimulus, such a star or an optical illusion, for a period of time, there is an apparent splitting
of the lines, as well as a fading of lines or whole wedges of the stimulus. These characteristics are not
found in parvocellular (PC) ganglion cells, the other type of ganglion cell. This indicates that MC cells
dominate during fixational eye movements, as their properties are such that this would happen. In the
diagram below, it is shown that in fixational eye movements, such as staring at the star shaped stimulus
(A), MC cells exhibit more line fading and splitting than PC cells. (Hennig M.H. et al 2007)
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(Hennig M.H. et al, 2007)
Intrinsically photosensitive retinal ganglion cells (ipRGCs), or melanopsin-positive ganglion cells,
are ganglion cells that function as a circadian photoreceptor. Mice with severe degeneration of rods and
cones, or with no rods and cones at all, still follow circadian rhythms based on light. Light affects a
circadian phase by activating the retinohypothalamic tract, which connects ipRGCs to the
superchiasmatic nucleus, a part of the hypothalamus. The ipRGCs are the only ganglion cells found to
contain melanopsin, an opsin which is photosensitive, indicating that this is the part of the ipRGC that
makes it a photoreceptor. IpRGCs are different than the classical photoreceptors in that they depolarize
when stimulated by light, while rods and cones hyperpolarize. IpRGCs are also less sensitive and more
sluggish than the classic photoreceptors. The melanopsin-positive ganglion cells contribute to lightstimulated effects on sleep, heart rate, cortisol levels, alertness and other effects of the circadian cycle.
The pupillary light reflex, where light causes the size of the pupil to decrease and darkness causes the
pupil to dilate, is controlled by ipRGCs as well. The cells also perform the normal function of ganglion
cells, receiving synaptic input from bipolar and amacrine cells. (Berson D. M. 2003)

Müller Cells
Müller cells, a specific type of glial cell, fill the spaces between the photoreceptors,
bipolar cells, ganglion cells, and other cells in the visual pathway. Müller cells are not part of the visual
pathway; they do not synapse with any cells, and they do not receive or send signals. Their function is
mainly to support and regulate the retina. The nuclei of Müller cells are found in the inner nuclear layer,
and their cytoplasmic processes extend to the outer and the inner limiting membranes. The inner
limiting membrane, which separates the retina from the vitreous body, is made up of the basal lamina of
Müller cells. The outer limiting membrane is located at the contact site where zonula adherens and
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microvilli extending from Müller cells connect the photoreceptors with the glial Müller cells.
(Kierszenbaum A.L. 2007)

(Dyer, M.A. et. al., 2001)
Before reaching the photoreceptors, light has to go through each layer of the retina. At each
layer, the light is refracted by the cells in that layer, ultimately causing less light to fall on the
photoreceptors. The Müller cells have a higher refractive index than the other cells, which means that
light can be channeled through the cells with little loss, so most of the light hitting the retina is received
by the photoreceptors. This high refractive index is caused by the tight bundles of polymer fibers that
extend along their lengths. (Castelvecchi, D. 2007)
Müller cells have many different functions in the retina. They regulate extracellular space, and
ion and water levels. They maintain the blood-retinal barrier, and retinal blood flow. They provide
trophic substances to the nerve cells, and they remove neural waste, such as carbon dioxide and
ammonia. (Kolb H. et al 1996) They also modulate neuronal excitability and transmission by sending
gliotransmitters to the neurons. They also supply the end product of anaerobic metabolism, they break
down glycogen, so that the nerve cells in the retina can perform aerobic metabolism. Müller cells and
astrocytes, another type of glial cell found in the retina, remove glutamate, an excitatory
neurotransmitter, and gamma-Aminobutyric acid (GABA), an inhibitory neurotransmitter from the
extracellular sites in the retina. Müller cells take up glutamate by utilizing glutamate transporters like
GLAST, glutamate-aspartate transporter, and convert it into glutamine with the enzyme glutamine
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synthetase. If the glutamate transporter is malfunctioning, the extracellular glutamate levels rise to
excitotoxic levels, causing damage to the retina. Müller cells uptake GABA using GABA transporters
(GATs), and convert it to glutamate using GABA transaminase. (Bringmann A. et. al. 2009)

(Kolb H. et. al. 1996)
The fovea centralis is a unique portion of the retina where an abundance of light is absorbed
and as such contains no rods; only cones. These Müller cells provide the primary structural support for
the fovea centralis, binding the photoreceptor cells together. The cells are also a reservoir for retinal
xanthophyll, yellow accessory pigment, which is partly responsible for the low density of the cell
cytoplasm in the fovea. Müller cells in the fovea centralis also have a primary role in age related macular
hole formation, providing an anatomical substrate for schisis to occur. X-linked juvenile retinoschisis, the
abnormal splitting of the retina’s neurosensory layers, is thought to be caused by degeneration of the
inner portion of the Müller cells in the fovea centralis. (Gass J.D.M. 1999)
In addition to Müller cells and astrocytes, there are also other glial cells found in the retina.
Microglial cells are blood-derived immune cells which reside in the retina. They play important roles in
host defense against invading microorganisms and the initiation of inflammatory processes and tissue
repair. They are present in all layers of the retina. (Bringmann A. et. al. 2009)

Conclusion
At first glance, the reason for the retina’s interbranching visual pathway is hard to understand.
But, after putting together the functions of each type of retinal nerve cell, one sees that each cell is
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essential. The complexity of the pathway serves to clarify the messages coming into the eye, and to
prevent unnecessary information from being transmitted to the brain. Understanding how the retina
functions is important for doctors and scientists who are diagnosing and treating patients who have
nerve damage in the retina. Knowing the function of each area and cell type in the retina can help to
diagnose what area is damaged when seeing certain symptoms present, and treatment can then be
administered. We know that Müller cells in the fovea centralis have roles in X-linked juvenile
retinoschisis and age related macular hole formation. Further research is being done by foundations
such as the Retina Research Foundation in Houston, Texas, in order to further understand the function
of each nerve cell in the eye and how each cell can lead to ocular disease.
The intricacy of the eye, and especially the retina, which is such a small part of our body, is aweinspiring. It is amazing to learn the workings of vision, something that is done almost every waking
second, and to actually understand what is happening each moment in one’s eye.
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